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1. Introduction
There are few hematopoietic stem cells (HSCs) in the bone marrow of adult mammals; these
are required throughout life to replenish the short-lived mature blood cells of specific hema‐
topoietic lineages. HSCs have several biological functions including homeostasis control, re‐
generation, immune function and response to microorganisms and inflammation.
The regenerative potential of human HSCs is best illustrated by successful stem cell trans‐
plantation in patients with a variety of genetic disorders, acquired states of bone marrow
failure and cancer [1].
The first bone marrow transplantation took place in 1949 with studies that demonstrated the
protection provided to the spleen of mice given a dose of irradiation that would otherwise
be lethal. In 1960, studies in dogs provided important information about bone marrow
transplantation in exogamic species, results that are applicable to humans. It was demon‐
strated that dogs could bear 2-3 times the lethal dose of total body irradiation with an infu‐
sion of bone marrow cells collected and cryopreserved before irradiation [2,3].
At the same time that animal experiments were being carried out, a number of attempts
were made to treat humans with chemotherapy or irradiation associated with bone mar‐
row infusions [4].
The first  successful  allogeneic bone marrow graft  was achieved in a patient with leuke‐
mia, although the patient died due to the complications of chronic graft-versus-host dis‐
ease (GVHD) [5].
© 2013 Vansan Marangon et al.; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Currently, bone marrow transplantation is the treatment of choice for many hematologic
diseases with the course of transplant being dependent on several factors, including the
stage of the disease at transplant, the conditioning regimen, source of cells, genetic factors,
and the development of GVHD. The goal to this chapter is to show some genetic factors that
have a strong influence on hematopoietic stem cell transplantation (HSCT) outcomes, such
as the genes of the human leukocyte antigen (HLA) system located in the major histocom‐
patibility complex (MHC), and other genetic factors, including non-HLA genes that seem to
influence transplant outcomes and that are being studied to optimize donor selection. Non-
HLA genes mainly include killer cell immunoglobulin-like receptor (KIR) genes, cytokine
genes and receptors, MHC class I-related chain (MIC) genes and human minor histocompat‐
ibility antigens (mHAgs).
2. HLA immunogenetics and its influence on hematopoietic stem cell
transplantation
Histocompatibility
The immune system is the result of germline selection and thymic education (self vs. non-
self) through contact with pathogenic life and is thus a characteristic that is unique to each
individual and specific to a given point in time; like all other physiological systems, the im‐
mune system is affected by disease, stress, trauma and environmental events [6].
An important cell lineage within this system is represented by T lymphocytes. The main
functions of T lymphocytes are defense against intracellular microorganisms and the activa‐
tion of other cells including macrophages and B lymphocytes.
T lymphocytes are capable of interacting with other cells because the antigen receptors on T
cells recognize antigens that are presented by other cells; presentation is achieved by speci‐
alized proteins that are encoded by genes in a MHC locus [7]. The MHC system has the
greatest diversity of all functional genetic systems at the population level [6]. The MHC gly‐
coprotein family, also referred to as HLAs, presents endogenous and exogenous antigens to
T lymphocytes for recognition and response.
This system was discovered in mice by Peter Gorer and George Snell.  These researchers
discovered  an  antigen  which  was  involved  in  tumour  rejection  and  subsequently  they
showed that  similar  antigens in other strains of  mice were probably alleles  of  the same
“tumour-resistant” gene [8].
Experiments show that transplants of tissue between animals from the same population (en‐
dogamic) were successful, while the consequence of transplants between animals from dif‐
ferent populations (exogamous) was the rejection of tissue. The result of these studies was
the discovery of MHC genes which are capable of recognizing foreign antigens and present‐
ing them to T lymphocytes.
Antibodies induced by transfusions or pregnancy and which react with leukocyte antigens
were first recognized in 1954. Studies showed that kidney transplant patients who suffered
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rejection have circulating antibodies reactive to antigens present in leukocytes; as these anti‐
gens are expressed on leukocytes they were named HLAs [9,7].
Many studies were conducted over the next few years to understand and characterize the
immunogenicity of these antigens.
Structure and function
The MHC, contained within 4.2 Mbp of DNA on the short arm of chromosome 6 at 6p21.3,
has more than 200 genes, most of which have functions related to immunity. It is divided
into three main regions [10].
The HLA-A, -B and -C classic genes and -E, -F and -G non-classic genes, as well as other
genes and pseudogenes are located in the HLA Class I region near to the telomere. The HLA
Class II region, near to the centromere, contains the HLA-DR, -DQ and -DP genes. The
HLA-DR sub-region, includes the DRA gene that encodes the alpha chain is non-polymor‐
phic and can bind with any beta chain to encode for DRB genes [11].
Located between class I and II regions, the class III region has C2, C4A, C4B and B factor,
that encode complement proteins and the tumour necrosis factor (TNF) [10,11].
HLA molecules are polymorphic membrane glycoproteins found on the surface of nearly
all cells. Multiple genetic loci within the MHC encode these proteins with each individu‐
al  simultaneously  expressing  several  polymorphic  forms from a  large  pool  of  alleles  in
the  population.  The  overall  structure  of  HLA  class  I  and  class  II  molecules  is  similar,
with most of the polymorphisms found in the peptide binding groove (PBG) where anti‐
gens are recognized [12].
Class I molecules are made up of one heavy chain (45kD) encoded within the MHC and a
light chain called β2- microglobulin (12kD) whose gene is on chromosome 15. Class II mole‐
cules consist of one α (34kD) and one β chain (30kD) both within the MHC [10]
The class I heavy chain has three domains with the membrane-distal α1 and α2 domains be‐
ing polymorphic. Within these domains, polymorphisms concentrate in three regions: posi‐
tions 62 to 83, 92 to 121, and 135 to 157. These areas are called hypervariable regions. The
two polymorphic domains are encoded by exons 2 and 3 of the class I gene. Diversity in
these domains is very important because these two domains form the antigen binding cleft
or PBG of MHC class I molecules [13,14].
The sides of the antigen binding cleft are formed by α1 and α2, while the floor of the cleft is
comprised of eight anti-parallel β sheets. The antigenic peptides of eight to ten amino acids
(typically nonamers) bind to the cleft with low specificity but high stability. The α3 domain
contains a conserved seven amino acid loop (positions 223 to 229) which serves as a binding
site for CD8 [12,15-17].
Class II molecules consist of two transmembrane glycoproteins, the α and β chains which
are restricted to cells of the immune system (e.g. B cells, dendritic cells - DCs), but can be
induced by other cell types during immune response. The PBG of class II molecules has
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open ends which allow the peptide to extend beyond the groove at both ends and therefore
to be longer (12-24 amino acids). The peptide is presented to CD4 T cells [10].
Generally both the α and β chains in class II molecules are polymorphic. In these chains, the
α1 and β1 domains are of the PBG and therefore the diversity is found mainly in these do‐
mains. These domains are encoded by exon 2 of their class II A or B genes and the hyper‐
variable regions tend to be found in the walls of the groove [16].
T-cell activation occurs following recognition of peptide/MHC complexes on an antigen-pre‐
senting cell (APC). T-cell activation can be viewed as a series of intertwined steps, ultimately
resulting in the ability to secrete cytokines, replicate and perform various effector functions.
During antigen presentation, CD4 and CD8 are intimately associated with the T-cell receptor
and bind to the MHC molecule. Besides this interaction between T cells and APCs, ligation
between counter-receptors on the T cell and accessory molecules on the APC is required as
additional signals for T-cell activation [18].
Haplotype, Linkage Disequilibrium and Expression of HLA genes
HLA genes are transmitted following Mendel’s  law of segregation,  so the allelic  variant
is codominantly expressed. The set of alleles present in the HLA loci located in a single
chromosome of  a  chromosome pair  is  called a  haplotype.  The probability  that  two sib‐
lings having the same HLA haplotype is 25%; in this situation, it is considered that they
are matching [11].
Moreover, a fact called linkage disequilibrium occurs in HLA genes. This means that certain
alleles occur together at a higher frequency than would normally be expected by chance (ga‐
metic association). Consequently, some combinations of alleles appear more or less com‐
monly in a population than would normally be expected from a random formation of
haplotypes from alleles based on their frequencies [10].
For example, if a determined population has genic frequencies of 14% and 9% for HLA-A*01
and HLA-B*08, respectively, the expected frequency of a haplotype with this combination
would be 1.26% (0.14 x 0.09). However, the true frequency may be 8.8% in this population,
that is, higher than expected, characterizing a positive linkage disequilibrium [11].
Examples can be seen in studies of linkage disequilibrium related to bone marrow donation.
A strong linkage disequilibrium has been reported for HLA-B*39:13 with the DRB1*04:02,
DRB1*08:07 and A*31:12 haplotypes in the Brazilian population [19].
Other  reports  for  unrelated  donors  involved  HLA-A*01  and  HLA-B*08,  HLA-A*03  and
HLA-B*35  and  HLA-A*02  and  HLA-B*12.  This  type  of  results  suggests  that  these  data
have clinical  application,  such as  in  the  selection of  unrelated donors  for  bone marrow
transplantation [20].
HLA compatibility of donors
The genetic origin of patients for whom bone marrow transplantation has been proposed, is
a key determinant in the possibility of identifying compatible unrelated and sibling donors
and consequently in the possibility of performing the procedure.
Innovations in Stem Cell Transplantation6
The strict HLA compatibility that is required for bone marrow transplantation increases the
difficulties in finding donors. A patient has one chance in four of having a compatible donor
among his brothers and sisters. This chance becomes one in a million, on average, in unrelat‐
ed donors [21].
Different methods are used to identify HLA antigens. In the past, HLA antigens for bone
marrow transplantation were identified by serological  methods based in mixed lympho‐
cyte  culture.  However  this  technique  is  not  as  sensitive  as  molecular  biology  methods
which can define HLA antigens at the allele level.
In molecular analysis,  HLA genes can be identified by polymerase chain reaction (PCR)
using  the  Specific  Sequence  Primers  (SSP),  Specific  Sequence  Oligonucleotides  (SSO)  or
sequencing techniques. These methods are the most commonly used due to its specificity
and  sensibility  that  can  define  HLA  genes  only  (low  resolution)  or  genes  and  alleles
(high resolution).
These results are very important in bone marrow transplantation in order to choose the
best  matched  donor.  The  probability  of  finding  a  well-matched  unrelated  donor  is  im‐
proved if high resolution typing is available for the patient prior to the search. Therefore
typing must ideally be done by DNA methods to avoid hidden mismatches, particularly
in  the  case  of  antigenically  silent  alleles,  and  should  include  the  HLA-A,  -B,  -C  and  -
DRB1 genes at least [10].
Matched or mismatched donors
There are many studies which try to show that better outcomes in bone marrow transplanta‐
tion are linked to full donor matches. In 2004 the National Marrow Donor Program (NMDP)
published the results on the outcomes of 1874 unrelated donor transplants. This study
showed a highly significant survival advantage for 8/8 matched pairs compared to those
with one or two mismatches [22].
Moreover, the study of the Center for International Blood and Marrow Transplant Research
(CIBMTR) examined clinical outcomes in recipients of both sibling and unrelated donors for
chronic myeloid leukemia (CML) in the first chronic phase. There were 1052 recipients of
unrelated transplants; 531 were matched for 8/8 alleles, 252 mismatched for 1 (7/8) allele and
269 mismatched for multiple alleles [22]. The overall survival (OS) at 5 years was 55% for 8/8
matched transplant recipients, 40% for those with a 7/8 matched graft and 21-34% for those
with various multiple mismatched combinations. The recipients of stem cell matched related
donors, predominantly siblings, have lower risk of infections, of the reactivation of cytome‐
galovirus and of mortality than the latter group. Additionally, T-cell immunity reconstitu‐
tion is delayed in mismatched sibling donors and the unrelated group [23, 24].
Graft rejection, GVHD and delayed immune recovery, the major obstacles to successful allo‐
geneic HSCT, are more severe with unrelated donors than in HLA-identical sibling trans‐
plants. Because identical donors are available to only about 30% of patients, the
identification of a suitable unrelated donor by better, more precise HLA matching of donor
and recipient is necessary [25].
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Studies have shown strong negative effects of HLA mismatching of the HLA-A, -B, -C, -
DRB1 or -DQB1 loci on OS. The presence of multiple mismatches was worse for survival
and for severe acute GVHD (grade III-IV). Other trials analyzed the incidence of chronic
GVHD in patients who survived more than 100 days after transplantation. It became evident
that a HLA-A/B mismatch induces a significantly higher incidence of chronic GVHD and
lower OS rate. The same was not confirmed for a HLA-DQ/DR mismatch that showed no
association with the occurrence of chronic GVHD [25;26].
High resolution HLA typing can help in the characterization of donors; there are differences
in the outcomes of bone marrow transplantation if the mismatching of donors was defined
by low or high resolution. Studies show that high resolution matching of HLA-A, -B, -C and
-DRB1 between volunteer HSC donors and recipients is associated with a better survival.
Additionally, single HLA-B and -C mismatches appear to be better tolerated than single
HLA-A or -DRB1 mismatches [27].
Other studies affirm that survival after unrelated HSCT for severe acquired aplastic anemia
has improved significantly over the last 15 years mainly due to better HLA matching at the
allelic level [28].
HLA and bone marrow transplantation
The outcome of transplantation using unrelated donors is highly influenced by HLA match‐
ing between the donor and recipient. Two particular individuals always differ in their ge‐
nome structure in respect to minor histocompatibility antigens, killer cell immunoglobulin-
like receptor (KIR) genes and several other groups of genes.
However, the most potent transplantation antigens are the HLAs encoded by genes located
in the MHC. HLA-C is a class I gene locus, yet its importance in transplantation has been
less validated than the HLA-A and B loci [10].
However, studies that analyzed structure and peptide-binding for HLA-C, show that diver‐
gence in peptide-binding specificity may be a contributor to the risk of mortality after trans‐
plantation perhaps due to the alloreactivity of donor T cells towards peptides presented by
patient HLA molecules but not by donor antigens presenting cells during T-cell develop‐
ment in the thymus [29].
There are two main reasons for the HLA antibodies to result in graft failure and GVHD. The
first is the rapid increase in the number of HLA-mismatched HSCT, including in cord blood
transplantation, haploidentical HSCT and unrelated HSCT. The second is the technical ad‐
vance in the methods of HLA Ab testing, which have attained a rapid, accurate and objec‐
tive identification and qualification of specific HLA antibodies [30].
HLA, sibling and unrelated hematopoietic stem cell transplantation
Matched or mismatched
The use of stem cells from HLA-matched unrelated volunteer donors is an accepted option
for patients without a matching sibling donor providing comparable outcomes to matched
sibling donor HSCT. Many studies have been performed to compare the results between sib‐
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ling and unrelated transplantation. Other studies show single results about sibling and un‐
related transplantation, the importance of HLA compatibility and what effect HLA
mismatches may have on GVHD, graft failure and relapse.
Research has shown that HLA class II  DRB1*15 (*15:01 and *15:02) are important in the
outcome to sibling matched transplants for patients who have aplastic anemia. In multi‐
variate analysis, the secondary graft failure rate at two years was lower in patients who
were HLA-DR15+[31].
Recent studies in a Chinese population show that the outcome of unrelated donor transplan‐
tation matched for HLA-A, HLA-B and HLA-DRB1 but unknown for HLA-C antigens was
associated with a significant risk of mortality and that this risk was higher with HLA-A, B or
DRB1 mismatches compared to an 8/8 match [32].
Other studies confirm that there is no association between HLA mismatching of unrelated
donors with the cumulative incidence of grade II-IV or grade III-IV acute GVHD. Similarly,
there was no association with chronic GVHD, but the incidence of graft failure was higher in
HLA-mismatched unrelated transplants [33]. Trials highlight the importance of defining
HLA by high resolution techniques to improve the outcomes in pediatric transplants using
unrelated donors. The patients that suffered graft failure were mismatched for HLA-C by a
high resolution technique [34].
However, studies show that in unrelated transplantations, the outcome is improved when
the patients are HLA-C and HLA-DPB1 mismatched in some combinations, thus resulting in
lower risk of relapse. Probably some combinations increase the graft-versus-leukemia (GvL)
effect [35].
One study analyzed the impact  of  HLA class  I  and II  high-resolution matching of  1874
unrelated donors and found that HLA-C mismatching was most strongly associated with
graft  failure,  HLA-A  mismatching  was  associated  with  significantly  increased  risk  of
grade III/IV acute and chronic GVHD and mismatches of HLA-A, B, C and DR were as‐
sociated with death [36].
HLA and Haploidentical HSCT
When no matched sibling or unrelated donor exists, the potential curative option is haplo-
HSCT, that is, transplant with a donor who shares only one haplotype with the recipient.
Haploidentical stem cell transplants are increasingly used in the treatment of malignancies,
and immune and hematologic diseases. As multiple mismatched related donors may be
available for transplantation, it is important to select a donor that is most likely to produce a
successful outcome [37].
There are studies that correlate the HLA-B mismatch effect in haplo-HSCT. Studies analyzed
the impact of HLA-A, -B, -DRB1, -DRB3, -DRB4 and -DRB5 and demonstrated that a HLA-B
mismatch not only has a significant effect on GVHD and transplant-related mortality but
was also associated with reduced OS and leukemia-free-survival [38].
There is an important point in haploidentical transplants that should be considered: the con‐
ditioning regimen. Many protocols have been performed to improve the outcomes of trans‐
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http://dx.doi.org/10.5772/54281
9
plantation and to minimize the effect of HLA incompatibility. For example, studies on
nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose post-
transplant cyclophosphamide. The results showed that HLA mismatch was not associated
with relapse or GVHD [39].
In bone marrow transplantation with mismatch of the HLA-DRB1 antigen in the GVHD di‐
rection and two or more HLA Class I (HLA-A, -B and -Cw) mismatches in either direction
were found to be associated with decreased incidences of relapse without an increased inci‐
dence in nonmyeloablative conditioning with post-transplant cyclophosphamide [40].
HLA and cord blood transplantation
The use of umbilical cord blood transplantation (UCBT) for patients with hematological ma‐
lignances or hereditary diseases is becoming increasingly more common. In October 2006,
the International NETCORD Foundation maintained an inventory of more than 124,000 um‐
bilical cord blood (UCB) units and documented more than 4900 unrelated UCBT [41]. Sever‐
al studies have shown that the number of cells is the most important factor for engraftment,
while some degree of HLA mismatch is acceptable.
For example, studies show that unrelated UCBT is comparable to a 1-antigen mismatch at
the HLA-A, HLA-B or HLA-DR loci in respect to GVHD, relapse and OS [42]. For other
studies on UCBT, HLA-A and -B are defined by low-resolution and HLA-DRB1 by high-res‐
olution, with minimum compatibility of 4/6. It is important to apply the rules of equivalence
of serological groups for HLA-B*14, -B*15, -B*40, and -B*50 as determined by molecular
methods [43].
Clinical comparison studies of UCBT and HLA-A, -B and -DRB1 6/6 allele-matched bone
marrow transplantation or single mismatched for leukemia from unrelated donors in adult
recipients showed similar results. There was no significant increase of relapse rates among
UCB recipients when compared with DRB1 single-mismatched bone marrow recipients. The
OS for UCB recipients was similar too when compared with DRB1 single-mismatched bone
marrow recipients [44].
Korean pediatric studies also show that the results of UCBT are promising. One study com‐
pared the outcomes of acute leukemia children submitted to transplantation using UCB,
bone marrow and peripheral blood stem cells from HLA-matched or unrelated donors. The
results confirm that survival after UCBT was similar to survival after matched related donor
and unrelated donor transplantations. In conclusion, for patients lacking an HLA matched
donor, the use of UCB is a suitable alternative [45].
Additionally,  studies  show  that  recipients  of  UCB  transplants  from  HLA-identical  sib‐
lings have lower incidences of acute and chronic GVHD than recipients of bone marrow
transplants  from HLA-identical  siblings [46].  Hence,  studies  on the distribution of  HLA
alleles and haplotypes in different ethnic populations are also important to find a suita‐
ble unrelated cord blood donor for  a patient.  One study investigated the frequencies of
alleles and HLA-A, -B and -DRB1 haplotypes with high-resolution typing data in a total
of  710  Taiwanese  UCB  units  [47].  The  most  common  alleles  found  for  HLA-A  were
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A*11:01,  A*24:02,  A*33:03  and  A*02:01;  for  HLA-B  they  were  B*40:01,  B*46:01,  B*58:01
and  B*13:01  and  for  DRB1  they  were  DRB1*09:01,  DRB1*12:02,  DRB1*15:01  and
DRB1*03:01. Moreover, the five most frequently found haplotypes were A*11:01, B*35:05,
DRB1*11:02; A*24:07, B*35:05, DRB1*12:02; A*01:01, B*5701, DRB1*09:01; A*11:01, B*40:01,
DRB1*09:01  and A*11:01,  B*46:01,  DRB1*09:01.  These  haplotypes  are  common in  Taiwa‐
nese and Asian American populations [47].
Ethnic studies carried out in London showed that the most common alleles in 1500 UCB
units were HLA-A*34, A*36, A*80, HLA-B*75, B*61, B*53, B*78, B*81 and B*82. This kind of
study should help to increase the chances of obtaining acceptably HLA-matched donors for
patients from ethnic minorities [48].
3. Non-HLA immunogenetics and its influence on hematopoietic stem
cell transplantation
Natural killer cells and Killer immunoglobulin-like receptors
Human natural killer (NK) cells are components of the innate immune response that com‐
prise approximately 10-15% of all peripheral blood lymphocytes and play a major role in im‐
munity against viral infections and tumors [49-51]. Years of intensive research in mice and
humans have shown a special importance of NK cells in the hematological diseases and in
mediating favorable HSCT outcomes [52-57]. NK cells were first identified by their in vitro
capacity to kill tumor cells without the requirement of prior immune sensitization of the
host [58-59].
The function of NK cells is regulated by a diverse array of cell-surface receptors includ‐
ing KIR,  NKG2D and DNAM-1.  The KIR receptors,  in  the setting of  HSCT,  seem to be
the most important NK cell receptor family. These receptors can either inhibit or activate
NK cells with the difference between inhibitory and activating KIRs lying mainly in their
intracytoplasmic tail.  Inhibitory KIRs have long cytoplasmic tails  (KIR-L)  and activating
KIRs  have  short  cytoplasmic  tails  (KIR-S)  with  KIRs  having  two  or  three  Ig-domains
(KIR2D or KIR3D) [60-61].
In humans, the gene family encoding the KIR is located in the leukocyte receptor complex
(LRC) on chromosome 19q13.4. To date, 15 genes have been well characterized, of which 9
are NK cell inhibitors (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B,
KIR3DL1, KIR3DL2 and KIR3DL3), 6 are activating (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4,
KIR2DS5 and KIR3DS1), and 2 are pseudogenes (KIR2DP1 and KIR3DP1) [60-61]. An excep‐
tion is KIR2DL4 that although it has long tail it has an amino acid in the transmembrane re‐
gion that allows an association with an accessory protein, FceRI-g, which confers an
activating signal [62].
Individuals differ in the number and type of inherited KIR genes and the KIR haplotypes are
divided into two groups, A and B. The A or AA haplotype has a fixed number of genes, all
of which are inhibitory except for one activating gene (KIR2DS4). Haplotypes with addition‐
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al activating KIR genes (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1) or with KIR2DL5
are either AB or BB and are grouped together as KIR Bx haplotypes. Often, the KIR2DS4
gene is present in a deleted form and is not believed to be expressed at the cell surface. The
“framework genes”, KIR3DL2, KIR3DP1, KIR2DL4, and KIR3DL3, are common to both
groups of haplotypes [60-61, 63].
The KIRs interact with some HLA class I antigens on target cells. HLA-Bw4 and distinct al‐
lotypes of HLA-C (C1 and C2 groups) are the main ligands for most KIRs [64]. HLA-C al‐
leles are classified as C1 or C2 KIR ligand groups, depending on two amino acid positions
encoded in exon 2. HLA-C1 allotypes have serine at position 77 and asparagine at position
80 and are ligands for the KIR2DL2 and KIR2DL3 inhibitory receptors. HLA-C2 allotypes
have asparagine and lysine at positions 77 and 80, respectively and are ligands for the
KIR2DL1 inhibitory receptor and thought to be the ligand for the KIR2DS1 activating recep‐
tor [65-66]. HLA-Bw4 allotypes are characterized by at least 5 different patterns of amino
acids at positions 77 and 80-83 and are ligands for KIR3DL1. Some HLA-A alleles, namely
23:01, 24:02 and 32:01, are also ligands for KIR3DL1 [67-71]. In addition, HLA-A3 and HLA-
A11 are ligands for KIR3DL2; and HLA-A11 and some C1 and C2 allotypes are ligands for
KIR2DS4 [64, 72-74].The KIR gene and respective ligands are listed in Table 1.
KIR FUNCTION LIGAND
KIR2DL1 Inhibitory HLA-C group 2
KIR2DL2 Inhibitory HLA-C group 1
KIR2DL3 Inhibitory HLA-C group 1
KIR2DL4 Inhibitory, activating HLA-G
KIR2DL5 Inhibitory Unknown
KIR3DL1 Inhibitory HLA-B Bw4 and some HLA-A Bw4*
KIR3DL2 Inhibitory HLA-A3 and HLA-A11
KIR2DS1 Activating HLA-C group 2
KIR2DS2 Activating Unknown
KIR2DS3 Activating Unknown
KIR2DS4 Activating HLA-A11 and subsets of HLA-C group 1 and group 2
KIR2DS5 Activating Unknown
KIR3DS1 Activating Unknown
* HLA-A*23:01, HLA-A*24:02 and HLA-A*32:01
Table 1. KIR receptors and their HLA ligands
The mechanism of recognition of a target cell by NK cells differs from others lymphocytes.
[59] The NK cells are able to recognize a reduction or absence of self HLA class I ligands, as
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a form of distinguishing normal cells from target cells: this is the “missing-self recognition”.
It is well established that cancer cells and some infected cells develop various mechanisms
to escape lysis by T cells [75-76]. An effective mechanism is to decrease or remove complete‐
ly the HLA expression. The downregulation of HLA class I expression leads to resistance to
lysis by T lymphocytes but, as a consequence, can lead to a susceptibility to lysis by NK cells
[77-80]. During development, NK cells become licensed or educated by interaction with self-
HLA molecules to maintain tolerance to normal tissues. NK cells that do not express inhibi‐
tory receptors for self are retained in an anergic or hypofunctional state and those which
express inhibitory KIRs for self-HLA ligands are functionally active and thus can sense the
lack of expression of self HLA molecules on target cells which triggers lysis of these cells.
This is thought to be the main mode of action of NK cells [81-86].
Natural killer cell alloreactivity in hematopoietic stem cell transplantation
The clinical significance of missing-self recognition is especially evident in allogeneic HSCT.
In HSCT the NK cell alloreactivity is determined by an analysis of the donor’s KIR gene pro‐
file and by differences in MHC class I genes between the donor and the recipient. This can
be better explained by the presence in the donor of NK cells expressing inhibitory KIRs that
are not engaged by any of the HLA class I alleles present on the receptor [87]. As a conse‐
quence, donor NK cells become uninhibited and may display alloreactivity against mis‐
matched allogeneic targets [81-86].
Furthermore, NK cells are relevant in the setting of HSCT because they are the first lym‐
phoid cell subset to reconstitute after transplantation at a time when the adaptive immune
system is impaired. They have been detected in vivo in recipients within 1 to 3 months after
transplantation and up to 3 years after [88-91].
KIR model studies
Considering: 1) a strong correlation between the presence of KIR genes and their HLA li‐
gands and cytotoxicity and 2) the advent of methods of precise genetic characterization, it is
possible to determine the contributions of the various inhibitory and activating KIR genes in
HSCT [92]. There are several models to define NK alloreactivity by KIR incompatibility or
KIR mismatching, most of which are based on the analysis of KIR and HLA class I alleles. In
the ligand-ligand model, the KIR expression is assumed following HLA typing. In this mod‐
el, KIR ligands in recipients and donors are analyzed and at least one group of donor KIR
ligands must to be absent in the recipient’s KIR ligand repertoire. In the receptor-ligand
model, the KIR genes are typed for the donor and the HLA alleles are analyzed for recipi‐
ents and at least one of the inhibitory KIRs of the donor is not engaged in the recipient’s li‐
gand repertoire. Moreover some studies perform phenotypic analysis of inhibitory KIRs and
CD94/NKG2A in donor NK cells and also functional assays which can provide more infor‐
mation about the degree of alloreactivity of NK cells [87,93-94]. It is difficult to know which
model is the most adequate to select the KIR mismatch donor. Some authors suggest that an
increasing number of receptor-ligand mismatch pairs increase the potency of the anti-leuke‐
mia effect and also suggest that the receptor-ligand model could improve the accuracy of the
prediction of relapse rather than the ligand-ligand model in patients with lymphoid malig‐
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nancies [94]. However, it has not been well established and further studies are needed to
confirm this hypothesis.
In addition, a novel observation emerged that NK cells of maternal donors of HSCT provid‐
ed better protection from leukemia relapse than other related donors [95]. According to the
authors, the better outcome of mother-to-child transplantation may be the result of the con‐
tact of maternal immune cells with the semi-allogeneic placenta during pregnancy. It was
suggested that if further studies confirm the better outcomes of mother donors, it may be
incorporated as a donor selection criterion.
Another interesting aspect was shown in a recent study with patients that received unrelat‐
ed unmanipulated peripheral blood progenitor cells. The authors indicate that four-digit al‐
lele matching of HLA-C may have effects on the HSCT outcome dependent on the presence
of C1 and C2 KIR epitopes in the patients [96] suggesting the importance of analysis of
HLA-C at allele level for donor selection. While there are no common rules to select the best
donor according KIR compatibilities, all the findings must be analyzed.
KIR genes and haploidentical hematopoietic stem cell transplantation
Full-haplotype mismatched (haploidentical) HSCT is an option to treat patients lacking a
matched donor or a suitable UCB unit. In haploidentical HSCT (haplo-HSCT), the T cells
present  on  allogeneic  hematopoietic  grafts  are  important  to  promote  engraftment  and
mediate the GvL effect.  However,  they can also mediate GVHD [97-98].  These T-cell  re‐
sponses can be controlled by an appropriate intensity of immunosuppression by the con‐
ditioning  regimen.  The  T-cell  depletion  of  the  graft  help  prevent  GVHD  but,  as  a
consequence,  T-cell  depleted haplo-HSCT increases the risk of  graft  rejection and leuke‐
mic relapse.  In this  context,  the presence of  NK cell  alloreactivity in the GVH direction
seems to influence the prevention of leukemia relapse and has been investigated in sev‐
eral  preclinical  and  clinical  trials  [89,99-100].  It  has  been  observed  that  KIR-HLA  mis‐
matches  can  promote  clinical  benefits  in  haplo-HSCT  especially  in  patients  with  acute
myeloid leukemia (AML). In the first studies published by Ruggeri et al. [89,99] and the
more recent updates in 2007 [100] appropriate KIR-Ligand incompatibilities were associ‐
ated with a reduction in the risk of relapse of leukemia and graft rejection, and also pro‐
tection  against  GVHD  in  patients  with  AML.  These  results  were  supported  by  animal
models, in which the presence of NK alloreactivity was suggestive of a low incidence of
acute GVHD due to the killing of host APCs, which are critical for inducing donor T-cell
activation [101].  Similarly,  experimental  data  suggest  that  the  engraftment  rate  was  im‐
proved as a result of the lysis of residual host T lymphocytes by alloreactive donor NK
cells  [89,99,101-102]  and also  that  this  contributed  to  the  eradication  of  leukemia  blasts
that escaped from the conditioning regimen. These studies showed very good results and
led to a novel concept of mismatch to search for a transplant donor.  Since then, several
investigations based on KIR mismatching have been carried out with different outcomes.
In a study of patients that received haplo-HSCT with T-cell depletion [94] KIR incompatibili‐
ty (KIR-mismatch) was related to lower relapse rates in children with AML and also in chil‐
dren with acute lymphoid leukemia (ALL). Interesting, in the studies of Ruggeri et al.,
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patients with ALL were not susceptible to KIR-ligand mismatched haplo-HSCT. The differ‐
ent result in these two groups may be related to the fact that Ruggeri et al. studied only
adult patients. On the other hand, another recent study found no impact of KIR mismatch
on children with chemoresistant ALL that received T-cell depleted Haplo-HSCT [103]. In
general, NK cell alloreactivity seems to positively influence patients with myeloid malignan‐
cies and may benefit childhood ALL patients, but further studies are needed to confirm this.
A positive effect of NK cells on the outcome of haplo-HSCT in paedriatic patients was dem‐
onstrated in another study. The authors analyzed 21 children with different hematologic
malignances and found anti-leukemia activity of alloreactive NK cells in most transplanted
patients. They found that the NK cells derived from the donor were capable to selectively
killing C1/C1 target cells, including the patient’s leukemia blasts. Additionally, KIR2DL2/3+
NK cells that co-expressed KIR2DS1 killed C2/C2 leukemic blasts. These data suggest that
the presence of KIR2DS1 in alloreactive NK cells may mediate potent cytotoxicity [91]. In
agreement, in another study, the KIR2DS1 expression in alloreactive NK cells conferred an
advantage in the ability of NK cells to kill C2/C2 or C1/C2 myelomonocytic DCs and T-cell
blasts [104]. Another recent study examined 86 patients with advanced hematologic malig‐
nancies who received nonmyeloablative, HLA-haploidentical HSCT with high-dose, post-
transplantation cyclophosphamide. The inhibitory KIR gene mismatches between donor and
recipient, or KIR haplotype AA transplant recipients of KIR genotype Bx donors, were asso‐
ciated with lower relapse and non-relapse mortality (NRM) and improved OS and event-
free survival [105].
Nevertheless, other studies failed in find any association with KIR incompatibilities in the
GVHD direction [106], or found worse outcomes of transplantation for donors with the po‐
tential to NK alloreactivity [107]. Using the ligand-ligand model in a study of 62 patients
with ALL, AML and CML, the KIR mismatch was associated to considerably lower OS and a
higher incidence of GVHD [107].
KIR genes and unrelated hematopoietic stem cell transplantation
The impact of KIR-ligand mismatching in HSCT using unrelated donors has been associated
with controversial results. Beneficial outcomes have been shown in some studies. Unrelated
HSCT KIR-ligand incompatibility was associated with a reduced incidence of grade III-IV
acute GVHD and a better OS and disease free survival (DFS) in an analysis of 130 patients with
different  hematological  malignances.  The  conditioning  regimen included  anti-thymocyte
globulin (ATG) for T-cell depletion and the association with DFS remained significant even
when patients with myeloid diseases were analyzed separately [108]. KIR-HLA incompatibili‐
ties were also associated with low rates of leukemic relapse in a study of 374 patients with mye‐
loid malignances submitted to T-cell replete unrelated HSCT [109]. In this study, in spite of this
beneficial result, the rates of graft failure were higher and there were no significant differences
in DFS or transplant-related mortality. A large study described an advantage of donor NK al‐
loreactivity; the authors analyzed 1770 patients of several centers and found that the absence of
HLA-C2 or HLA-Bw4 ligands but not mismatches were associated with a decreased risk of re‐
lapse in recipients receiving unmanipulated grafts from unrelated donors [110].
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Although most studies focus on the effect of the lack of inhibitory KIRs by their HLA class I
pair, some studies have shown interesting results about the role of activating KIRs and KIR
genotypes in unrelated HSCT. Certain B haplotype KIR groups have also been found to favora‐
bly affect the outcome after T-cell depleted HLA-identical sibling transplants [111]. In 2009 a
study showed that donor group B haplotypes significantly improve graft survival in AML pa‐
tients submitted to T-replete unrelated HSCT [112]. The same group in a recent report recon‐
firmed the influence of the B haplotype on transplantation outcome. They published a large
study of 1409 unrelated transplants for AML and ALL and analyzed centromeric and telomeric
gene-content motifs in both group A and B KIR haplotypes. They suggest that centromeric and
telomeric motifs present in B haplotypes could promote protection against leukemic relapse, as
well as, improve survival. Moreover, they found a reduced relapse in those patients whose do‐
nors had 2 or more B gene-content motifs [113]. In addition, in a prospective study, the pres‐
ence of the B KIR genotype in donors was also related to fewer bacterial infections at six months
post transplant in recipients of unrelated HSCT [114]. In fact it has been observed that some ac‐
tivating genes present in Haplotype B may have an influence on unrelated HSCT. The presence
of KIR3DS1 in the donor has been associated with reduced grade II-IV acute GVHD and a low‐
er transplantation-related mortality rate [115-116]. Donor KIR2DS1 in isolation or in associa‐
tion to KIR2DS2 appears to provide protection against relapse in unrelated HSCT [116-117]. On
the other hand, in an analysis of patients and their respective HLA-identical sibling or unrelat‐
ed donors, KIR2DS1 in the donor and the absence of this gene in the receptor was associated
with increased risk of acute GVHD, KIR2DS3 was associated to chronic GVHD and KIR2DS5
was associated to relapse [118]. Another study also demonstrated deleterious effects of activat‐
ing KIRs; an increased number of donor activating KIR genes was suggested to be a significant
factor in the probability of relapse. The KIR-ligand mismatch pairs were a risk factor for trans‐
plant-related mortality [119]. The effect of activating KIRs was mainly found in AML and mye‐
lodysplastic syndrome (MDS) patients. The conditioning regimen included using ATG for in
vivo T-cell depletion.
As discussed above, there are several studies describing improved outcomes based on KIR-
ligand mismatching, however, most studies have reported no advantage [120-123] or worse
outcomes for KIR-ligand mismatch donors in unrelated HSCT. Deleterious results included
lower OS in patients with myeloid malignances submitted to KIR-ligand mismatch HSCT
[120] increased infection rates [124]; increased probability of leukemic relapse [125] in‐
creased rates of rejection and association with acute Grade III and IV GVHD [126].
KIR genes and sibling hematopoietic stem cell transplantation
On applying KIR genotyping, some studies investigated the effect of KIR in sibling HSCT. A
study of 220 donor-recipient pairs in HLA-matched sibling HSCTs found that patients with
myeloid disease who were homozygous for the C2 group had worse OS than patients who
were either homozygous or heterozygous for a C1 group. This effect was seen only in patients
who received a graft from a donor carrying the KIR2DS2 gene and only for patients with mye‐
loid disease (no effect was seen in patients with lymphoid disease) [127]. In another study the
KIR-ligand mismatch was associated to better DFS and OS and lower incidence of relapse in pa‐
tients with AML and MDS that received T-cell depleted HLA-identical sibling transplants.
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AML and MDS patients who lacked two HLA ligands for donor-inhibitory KIR had the highest
DFS and OS. Interesting, these results were found only for AML and MDS patients and not for
CML or ALL patients [128]. Benefits were also described for AML and MDS patients in another
study; the authors found a reduced risk for relapse in patients undergoing HLA-identical sib‐
ling HSCT who both received a high (above-median) NK cell number and lacked at least one
HLA-B or HLA-C ligand of the donor’s inhibitory KIRs. Transplants with more than two differ‐
ent activating donor KIRs were associated with an increased risk for non-relapse mortality
[129]. In another study, KIR-genotyping of 246 T-cell depleted HSCTs with HLA-identical sib‐
ling donors was performed; the 2DL5A, 2DS1, and 3DS1 KIR genes were associated with signif‐
icantly less relapse in patients with AML but not in patients with other myelogenous or
lymphoid malignancies. All these findings suggest that NK cells have implications in donor se‐
lection for myeloid diseases especially for AML patients [130].
Some studies have investigated KIR genes in respect to post-transplant infections in sibling
HSCT. In one study, additional activating KIR genes in the donor compared to the recipi‐
ent's genotype were associated with lower transplant related mortality, better survival, and
a reduced incidence of cytomegalovirus (CMV) reactivation [131]. In another study of T-cell
replete HSCT from matched sibling donors, the presence of donor KIR haplotype B was as‐
sociated with a 65% reduction in CMV reactivation [132]. Moreover, in another the presence
of specific activating KIR haplotypes in the donor was associated with protection from CMV
reactivation in patients submitted to sibling and unrelated HSCT [133]. Other researchers
analyzed patients according to the combination of group A and B KIR haplotypes in the
transplant donor and recipient and found a higher OS when the donor lacked and the recipi‐
ent had group B KIR haplotypes. Moreover, the poorest OS rate and increased relapse and
acute GVHD were recorded when the donor had and the recipient lacked group B KIR hap‐
lotypes and both were homozygous for the C1 KIR ligand. The presence of the Bw4 ligand
was also associated with increased acute GVHD. In contrast, the presence of both KIR3DL1
and its cognate Bw4 ligand was associated with decreased non-relapse mortality. An analy‐
sis of KIR genes individually revealed KIR2DS3 as a protective factor for chronic GVHD
[134]. In another study, 60 AML patients submitted to T-cell replete HLA-matched related
donor allogeneic bone marrow transplants were analyzed. Heterozygous C1/C2 patients
had significantly worse survival than those homozygous for C1 or C2 and the C1/C2 group
had a higher relapse rate. Multivariate analysis found C1/C2 status to be an independent
predictor for mortality. Since C1/C2 heterozygotes have a greater opportunity to engage in‐
hibitory KIRs than C1 or C2 homozygotes, they may more effectively inhibit KIR-positive
NK cell and T cell populations involved in GvL responses [135].
KIR genes and autologous stem cell transplantation
Few research groups have demonstrated the influence of KIR genes in autologous stem cell
transplantation (ASCT). The interest in the role of KIR genes in the setting of ASCT is mainly
related to preventing relapse, the main cause of treatment failure. Some studies have shown
that rapid and early NK cell recovery following ASCT is associated with a better progres‐
sion-free survival (PFS) in some diseases. An analysis of 182 patients with myeloma multi‐
ple submitted to ASCT showed a worse outcome in patients who were KIR3DS1+. The
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KIR3DS1 genotype was associated with a shorter PFS with the effect being more notable in
patients who received a transplant while in complete or partial remission after induction
chemotherapy and those who lacked HLA-Bw4 [136].
Similarly, in a study of 169 neuroblastoma patients treated by ASCT, a survival advantage
was shown in patients lacking HLA class I ligands for autologous inhibitory KIRs. Those
who lacked the HLA-C1 ligand for KIR2DL2/ KIR2DL3 had the highest 3-year survival rate
[137]. Another study analyzed the influence of KIR mismatch in ASCT by the receptor-li‐
gand mismatch model. The study, involving 16 patients who were submitted to ASCT for
non-Hodgkin’s lymphoma and solid tumours, found a reduced relapse rate for patients
with an inhibitory KIR-HLA mismatch [138]. On the other hand, another study of 67 pa‐
tients with solid tumors or lymphomas who were treated with ASCT did not find any effect
of KIR-ligand interactions on the outcomes of ASCT [139].
KIR genes and unrelated umbilical cord blood transplantation
Unrelated UCBT has proved to be a viable treatment option. An advantage of using UCB is the
relatively low risk of acute GVHD due to a lower number of mature donor T cells and thus an
increased possibility of using HLA-mismatched units. Moreover, UCBT, as in haplo-HSCT, is
characterized by a rapid post-transplant recovery of NK cells. An analysis of 218 patients with
AML or ALL showed that patients who received a single UCBT unit from a KIR ligand incom‐
patible donor showed a lower incidence of relapse, and increased DFS and OS [140]. Addition‐
ally, as was seen in the Ruggery studies, the benefits were significantly more marked in
patients with AML. However, another study failed to observe any benefit of KIR-ligand mis‐
match in 155 recipients of UCB after myeloablative conditioning. In fact, in 102 patients who re‐
ceived UCB after nonmyeloablative conditioning, KIR-Ligand mismatch was associated with
an increased rate of acute GVHD and higher treatment-related mortality [141].
Altogether these data show that simple assessments of the KIR genotype might help in the
selection of donors for HSCT. KIR mismatches seem to be effective in haplo-HSCT and
mainly in patients with myeloid diseases. The contradictory results reported about the influ‐
ence of KIR mismatches in the diverse types of HSCT can certainly be explained by differen‐
ces in the transplant protocols employed. Differences like number of patients analyzed, type
of disease studied, stage of the disease, patient age, conditioning regimen, stem cell source,
GVHD prophylaxis and variability in the definition of KIR mismatch can influence trans‐
plant outcomes. Factors like T-cell depletion and no post-transplant immune suppression
seem to be important in maximizing NK cell alloreactivity [142].
Cytokines genes and receptors in HSCT
There are many other genetic factors that influence to outcome of transplant,  independ‐
ent  of  whether  the transplant  is  autologous,  allogeneic,  matched or  mismatched,  sibling
or unrelated donor, or haploidentical and of whether the cell source is bone marrow, pe‐
ripheral blood or UCB.
The goal of the majority to studies is to know what kind of influence these genetic factors
and HLA compatibility have and what effect they have on the course of the transplant: acute
and chronic GVHD, relapse, OS and mortality.
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One important factor is the polymorphisms within the regulatory sequences of cytokine
genes. Proinflammatory cytokines, receptors and related inhibitors have been implicated in
a large number of immune diseases. The main role of cytokine genes is related to the immu‐
nopathogenesis of GVHD [143].
Studies on cytokine genes in the transplant setting involve receptors of the TNF, IL-10, the
IL-1 gene family, IL-2, IL-6, interferon TNF-γ, TGF-β1 and TGF-β1 [28, 144-145].
Tissue injury, including of the mucosa and liver, occurs during the conditioning regimen.
This process causes the secretion of the TNF-α, IL-6 and IL-1 pro-inflammatory cytokines
that increase HLA antigens, thus increasing the antigens recognized by donor T-cell recep‐
tors in allogeneic transplantation. Moreover, during the activation to donor cells, T cells pro‐
duce IL-2 and INF-γ (Th1) that trigger GVHD and are balanced for Th2 cytokines such as
IL-4 and IL-10 [146-147].
Studies on allogeneic HSCT, investigated 16 patients with chronic GVHD by a systematic
clinical examination of the oral cavity, and by biopsies of the buccal mucosa and labial sali‐
vary glands. The findings demonstrated that the mRNA expression of IL-2, INF-γ, IL-4 and
IL-5 in the buccal mucosa of chronic GVHD patients was greater than in control individuals.
A similar result was detected for the labial salivary glands with the addition of IL-10 [148].
Studies show that IL-2 and INF-γ were detected more frequently in patients with acute
GVHD. Additionally, IL-12 and IL-18 were increased while IL-10 was decreased in the same
group, and IL-4 did not present a significant difference between the control and patient
groups [144]. Other studies show high IL-10 gene expression in the recipient that may be re‐
lated to a reduced incidence of grades II to IV acute GVHD and a reduced graft-versus-tu‐
mor effect after HSCT with nonmyeloablative conditioning [145].
On the other hand, studies affirm that IL-4 producing cells inhibit the development of acute
GVHD and the increased percentage of IL-4 secreting cells may be responsible for the unex‐
pected low incidence of acute GVHD after peripheral blood HSCT, despite the presence of
large numbers of mature T cells in the donor infusion [148].
Many studies show that polymorphisms of cytokine genes influence to outcome of trans‐
plants, such as with the development of GVHD. One example is that the IL17+197ª allele was
associated with increased risk of grade III and IV acute and chronic GVHD. Other studies
demonstrate clinically important relationships between genetic polymorphisms in TNF-α
and the severity of acute GVHD [147,149]. There are many other associations of polymor‐
phisms of cytokine genes that course to acute and chronic GVHD.
Major histocompatibility complex class I-related chain genes and HSCT
The MHC class I-related chain (MIC) genes have been the subject of interest in the setting of
HSCT. This family of genes, located in the MHC classical class I region, was first described
in 1994 [150-151]. These genes are very polymorphic, but not as much as the classical HLA
class I genes. Humans have seven MIC genes, named MICA to MICG but only two MIC
genes are functional, the MHC class I-related chain A (MICA) and B (MICB) genes. The MIC
proteins are similar to the HLA class I gene products however they are not associated with
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β-2-microglobulin and also do not bind peptides to present to T cells [150,152]. MIC proteins
appear to be induced by stress [153] and are expressed on the cell surface of fibroblasts and
endothelium cells [154]. They are ligands for NKG2D [155], a receptor present on NK cells
and some T cells, and because of this they can co-stimulate NK cells and T cells and can
therefore determine the outcome of certain effector functions that are related to GVHD. In
fact, MIC genes have been show to be attractive targets in diverse cancers, autoimmune dis‐
eases and in organ rejection after transplantation.
Several studies have demonstrated that the MICA may be a target molecule in allograft re‐
jection because MICA can elicit antibody production after solid organ transplantation
[156-163]. Some studies have reported diverse outcomes in HSCT related to MIC genes. It
was suggested that MIC genes play a role in GVHD in HLA-matched HSCT because a high‐
er rate of grade II-IV acute GVHD was found as was more gastrointestinal GVHD in MICA
mismatched patients [164]. In addition, matches of MICA and MICB loci were shown to in‐
crease patient survival in a study of 44 patients who received unrelated HSCT [165].
Some polymorphisms in MICA genes have also been associated to outcomes in transplants.
A change at position 129 of the α2-heavy chain domain of MICA can denote the strength of
interaction with the NKG2D receptor. The presence of methionine at position 129 of the MI‐
CA gene characterizes a strong binder, and the presence of valine characterizes a weak bind‐
er [166]. Hence, the MICA-129 valine genotype and soluble MICA serum level were
considered risk factors for chronic GVHD in a study of 211 HLA-identical sibling pairs of
HSCT while before transplantation, the presence of anti-MICA antibodies that can neutralize
soluble MICA confers protection [167]. Altogether, these data suggest that MIC genes, in
particular the MICA genes, could be used as biomarkers for chronic GVHD and should be
studied further.
Minor histocompatibility antigens and HSCT
The human minor histocompatibility antigens (mHAgs) are another group of immunogenic
peptides, distinct from the MHC system, which seem to have a role in HSCT outcomes.
They are derived from intracellular polymorphic proteins and are presented by HLA class I
and II restricted T cells [168-170]. Accumulated evidence suggests that they can elicit alloge‐
neic T-cell mediated immune response in HLA-matched allogeneic HSCT and because of
this have been investigated in order to understand their possible role in the control of
GVHD and GvL.
Diverse minor histocompatibility antigens of various genetic and cellular origins have been
described. More than 40 different genes that encode mHAgs recognized by either CD8+ or
CD4+ T cells have been identified [171-174]. Most of the mHAgs are result of non-synony‐
mous single nucleotide polymorphisms in autosomal genes while others are encoded by the
sex chromosomes. At least 6 genes in the Y chromosome encode male-specific MHAgs (so-
called HY antigens). Additionally, mHAgs may also be caused by gene deletions and genet‐
ic variations in non-coding regions affecting gene transcription [175-178].
The best-characterized minor histocompatibility antigen is encoded by the Y chromosome
(HA-1). The mHAgs related to gender seems to be involved in HSCT outcomes because their
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absence in women can lead to a response to male antigens; female-to-male transplants seem
to be more susceptible to GVHD [168-170, 179-180,181-185]. Antibody responses to HY pro‐
teins are also associated with both chronic GVHD and the maintenance of remission [186],
but whether these antibody responses contribute meaningfully to GVHD, or simply serve as
markers for it, remains unclear. In spite of female-to-male immune responses being more
common, the opposite can also happen [187-188].
Some mHAgs are expressed only in the hematopoietic system while others are also ex‐
pressed in normal tissues. mHAgs whose expression is limited to hematopoietic tissue may
be recognized by specific donor T cells and may selectively contribute to a GvL effect and
those with broad tissue expression may mediate GVHD [189].
Several studies have associated the presence of mHAg-specific T cells post-transplantation
with graft rejection [179, 190], GVHD [191-194], and the GVL effect [195-197]. Mismatches
between patient and donor for HA-1, HA-2, HA-4 and HA-5 are associated with an in‐
creased incidence in GVHD [191].
The  role  and  the  mechanisms  of  alloreactions  related  to  mHAgs  are  not  fully  under‐
stood, but these data suggest that they may be relevant in determining post-transplanta‐
tion outcomes.
4. Conclusion
Genetic differences between donor and recipient are crucial factors capable of influencing
transplantation outcomes. Much has been learned about the HLA and non-HLA genes, their
expression, their polymorphisms and their role in mediating GvL and GVHD responses. A
better understanding of these genes may permit more refined donor selection criteria and
consequently a more accurate assessment of transplant-related complications.
Author details
Amanda Vansan Marangon, Ana Maria Sell, Daniela Maira Cardozo and
Jeane E. L. Visentainer
Immunogenetics Laboratory, Department of Basic Sciences, Maringá State University -
UEM, Maringá, Paraná, Brazil
References
[1] Apperley J, Carreras E, Gluckman E, Masszi T. Haematopoietic Stem Cell Transplan‐
tation 2012. European School of Haematology, 74-89; 2012.
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
21
[2] Jacobson LO, Marks EK, Robson MJ. Effect of spleen protection on mortality follow‐
ing x-irradiation. J Lab Clin Med 1949;34:1538-43.
[3] Van Bekkun DW, DeVries MJ. Radiation Chimeras 1967. New York: Academic Press,
1967.
[4] Thomas ED, Lochte HL, Lu WC, Ferrebe JW. Intravenous infusion of bone marrow in
patients receiving radiation and chemotherapy. N Engl J Med 1957;257:491-6. http://
www.ncbi.nlm.nih.gov/pubmed/13464965 (accessed 02 August 2012).
[5] Mathé G, Amiel J.L, Schwarzenberg L, Catan A, Schneider M. Adoptive immuno‐
therapy of acude leukemia : experimental and clinical results. Cancer Res
1965;25:1525-31. http://www.ncbi.nlm.nih.gov/pubmed/5323965 (accesses 02 August
2012).
[6] Charron D. HLA, immunogenetics, pharmacogenetics and personalized medicine.
Vox Sanguinis, 2011; 100: 163-6. http://www.ncbi.nlm.nih.gov/pubmed?term=HLA
%20immunogenetics%20pharmacogenetics%20and%20personalized%20medicine
(accessed 08 August 2012).
[7] Abbas A. K, Celular and Molecular Immunology. 5th ed. 2005.
[8] Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching
contributes to the success of unrelated donor marrow transplantation. Blood 2007;
110:4576-83. http://bloodjournal.hematologylibrary.org/content/110/13/4576.long (ac‐
cessed 10 August 2012).
[9] Miescher PP, Fauconnet M. Mise en evidence de different groups leucocytaires chez
l’homme. Schweiz Med Wochenschr 1954;84:597-9. http://www.ncbi.nlm.nih.gov/
pubmed/13168327 (accessed 13 August 2012)
[10] Jawdat D, Al Saleh S, Sutton P, Al Anazi H, Shubaili A, Uyar FA, et al. HLA-C Poly‐
morphisms in two cohorts of donors of bone marrow transplantation. Saudi J Kidney
Dis Transpl.2012;23:467-70. http://www.sjkdt.org/article.asp?issn=1319-
2442;year=2012;volume=23;issue=3;spage=467;epage=470;aulast=Jawdat (accessed 13
August 2012).
[11] Voltarelli J. C, Pasquini R, Ortega E. T. T, Transplante de Células-Tronco Hemato‐
poiéticas. Ed. Atheneu 2010
[12] Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Struc‐
ture of the human class I histocompatibility antigen, HLA-A2. J Immunol
2005;174:6-9. http://www.jimmunol.org/content/174/1/6.long (accessed 13 August
2012).
[13] Steinmetz M, Hood L. Genes of the major histocompatibility complex in mouse and
man. Science 1983; 222: 727-33. http://www.sciencemag.org/content/
222/4625/727.long (accessed 14 August 2012)
[14] Le Bouteiller P. HLA class I chromosomal region, genes, and products: facts and
questions. Critical Reviews in Immunology 1994; 14: 89-129. http://
Innovations in Stem Cell Transplantation22
www.ncbi.nlm.nih.gov/pubmed?term=HLA%20class%20I%20chromosomal%20re‐
gion%2C%20genes%2C%20and%20products%3A%2 (accessed 16 August 2012).
[15] Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The for‐
eign antigen binding site and T cell recognition regions of class I histocompatibility
antigens. Nature 1987;329:512-8. http://www.nature.com/nature/journal/v329/
n6139/abs/329512a0.html (accessed 18 August 2012).
[16] Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first list‐
ing. Immunogenetics 1995;41:178-28. http://www.ncbi.nlm.nih.gov/pubmed?
term=MHC%20ligands%20and%20peptide%20motifs%3A%20first%20listing (ac‐
cessed 29 August 2012).
[17] Salter RD, Benjamin RJ, Wesley PK, et al. A binding site for the T-cell co-receptor
CD8 on the alpha 3 domain of HLA-A2. Nature 1990;345:41-6. http://
www.nature.com/nature/journal/v345/n6270/abs/345041a0.html (accessed 30 August
2012).
[18] Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T
cell response. Crit Rev Immunol 1997; 17:89-118. http://www.ncbi.nlm.nih.gov/
pubmed?term=Accessory%20molecule%20and%20costimulation%20requirements
%20for%20CD4%20T%20cell%20response (accessed 02 September 2012).
[19] Moraes M. E, Romero M, Salomão I, Correa M, Gouvea N, Romero M et. al, Strong
linkage disequilibrium between HLA-B*3913 and DRB1*0807 in Brazilians. Trans‐
plant. Proc. 2004; 36: 823-4. http://www.transplantation-proceedings.org/article/
S0041-1345(04)00328-8/abstract (accessed 03 September 2012).
[20] Vojvodic S, Popovic S, and Macukanovic G. L. Implications of HLA linkage disequili‐
brium phenomenon in finding unrelated volunteer bone marrow donors. Med. Preql.
2007; 60: 178-82. http://www.ncbi.nlm.nih.gov/pubmed?term=Implications%20of
%20HLA%20linkage%20disequilibrium%20phenomenon%20in%20finding%20unre‐
lated%20volunteer%20bone% (accessed 04 September 2012).
[21] Marry E. Genetics diversity and bone marrow transplantation. Bull Soc Pathol Exot.
2012; May;105(2):137-42. http://www.springerlink.com/content/y48r78g80384716x/
(accessed 13 September 2012).
[22] Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horo‐
witz M et al. Impact of HLA class I and class II high-resolution matching on out‐
comes of unrelated donor bone marrow transplantation: HLA-C mismatching is
associated with strong adverse effect on transplantation outcome. Blood, 2004; 104:
1923-30. http://bloodjournal.hematologylibrary.org/content/104/7/1923.long (accessed
14 September 2012).
[23] Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK et al.
HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor
bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol.
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
23
2009; 27:1644-1652. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668970/ (Ac‐
cessed 13 August 2012).
[24] Cheuk DKL, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, et al, Risk factors and mor‐
tality predictors of hepatic veno-occlusive disease, after pediatric hematopoietic stem
cell transplantation. Bone Marrow Transplant, 2007; 40: 935-44. http://
www.nature.com/bmt/journal/v40/n10/full/1705835a.html (accessed 29 September
2012).
[25] Loiseau P, Busson M, Balere M.L, Dormoy A, Bignon JD, Gagne K, et al. HLA associ‐
ation with Hematopoietic Stem Cell Transplantation Outcome: The number of mis‐
matches at HLA-A, -B, -C, -DRB1, or –DQB1 Is strongly associated with overall
survival. Biology of blood and marrow transplantation. 2007; 13:965-74. http://
www.bbmt.org/article/S1083-8791(07)00252-2/abstract (accessed 01 September 2012).
[26] Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical
significance of human leukocyte antigen (HLA) allele compatibility in patients re‐
ceiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR
matched unrelated donors. 2012; 99:4200-6. http://bloodjournal.hematologyli‐
brary.org/content/99/11/4200.long (accessed 06 August 2012).
[27] Lee S. J, Klein J, Haagenson M, Confer DL, Eapen M, Fernandez-Vina M et. al. High-
resolution donor recipient HLA matching contributes to the success of unrelated do‐
nor marrow transplantation. 2007; Blood. 110:4576-83. http://
bloodjournal.hematologylibrary.org/content/110/13/4576.long (accessed 23 Septem‐
ber 2012).
[28] Maury S, Appert B. L. M, Chir Z, Boiron J, , Galambrun C, Yakouben K, Bordigoni P
et. al. Unrelated stem cell transplantation for severe acquire aplastic anemia: im‐
proved outcome in the era of high-resolution HLA matching between donor and re‐
cipient. 2007. Hematologica Journal 2007; 92: 589-96. http://www.haematologica.org/
content/92/5/589.long (accessed 24 August 2012).
[29] Yanover C, Petersdorf EW, Malkki M, Gooley T, Spellman S, Velardi A et al. HLA
mismatches and hematopoietic cell transplantation: structural simulations assess the
impact of changes in peptide binding specificity on transplant outcome. Immunome
Research. 2011; 7:2:4. http://immunome-research.net/journal/index.php/immunome/
article/view//24 (accessed 14 September 2012).
[30] Yoshihara S, Tanigushi K, Ogawa H, Saji H, The role of HLA antibodies in allogeneic
SCT: is the type and screen strategy necessary not only for blood type but also for
HLA? Nature 2012; 1-8. http://www.nature.com/bmt/journal/vaop/ncurrent/full/
bmt2011249a.html (accessed 03 September 2012).
[31] Battiwalla M, Wang T, Carreras J, Deeg HJ, Ayas M, Bajwa RP et al, HLA-matched
sibling transplantation for severe aplastic anemia: Impact of HLA DR15 Antigens sta‐
tus on Engrafment, graft-versus-host disease, and overall survival. Biol Blood Mar‐
Innovations in Stem Cell Transplantation24
row Transplant. 2012;18:1401-6. http://www.bbmt.org/article/S1083-8791(12)00095-X/
abstract (accessed 13 September 2012).
[32] Wang T.F, Huang H, Tzeng CH, Wang PN, Wu T, Sun J, et al, Impact of donor char‐
acteristics and HLA matching on survival of Chinese patients with hematologic ma‐
lignancies undergoing unrelated hematopoietic stem cell transplantation. Biol Blood
Marrow Transplant. 2012; 1-6. http://www.bbmt.org/article/S1083-8791(12)00304-7/
abstract (accessed 13 September 2012).
[33] Horan J, Wang T, Haagenson M, Spellman SR, Dehn J, Eapen M et al, Evaluation of
HLA Maching in Unrelated Hematopoietic Stem Cell Transplantation for Nonmalig‐
nant Disorders. Blood 2012; http://bloodjournal.hematologylibrary.org/content/
120/14/2918.long (accessed 14 September 2012).
[34] Giebel S, Giorgiani G, Martinetti M, Zecca M, Maccario R, Salvaneschi L et. al, Low
incidence of severe acute graft-versus-host-diseasein children given haematopoietic
stem cell transplantation from unrelated donors prospectively matched for HLA
class I and II alleles with high-resolution molecular tiping. Bone Marrow Transplant.
2003; 31: 987-93.
[35] Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S et al, HLA mismatch
combinations associated with decreased risk of relapse: implications for the molecu‐
lar mechanism. Blood 2009; 113: 2851-8. http://bloodjournal.hematologylibrary.org/
content/113/12/2851.long (accessed 15 September 2012).
[36] Flomenberg N, Baxter-Lowe L, Confer D, Fernandez-Vina M, Filipovich A, Horowitz
MA, et. al, Impact of HLA class I and class II high-resolution matching on outcomes
of unrelated donor bone marrow transplantation: HLA-C mismatching is associated
with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923-30.
http://bloodjournal.hematologylibrary.org/content/104/7/1923.long (accessed 20 Sep‐
tember 2012).
[37] Ciurea S. O, Chaplim MDR. Donor selection in T-cell replete haploidentical stem cell
transplantation: Knowns, unknowns and controversies. Biol Blood Marrow Trans‐
plant. 2012; 319-9. http://www.bbmt.org/article/S1083-8791(12)00319-9/abstract (ac‐
cessed 20 September 2012).
[38] Huo MR, Xu LP, Li D, Liu DH, Liu KY, Chen H. et al, The effect of HLA disparity on
clinical outcome after HLA-haploidentical blood and marrow transplantation. Clin
Transplant 2012; 26:284-91. http://onlinelibrary.wiley.com/doi/10.1111/j.
1399-0012.2011.01499.x/abstract (accessed 20 September 2012).
[39] Kasamon Y. L, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J et al,
Nonmyeloblative HLA-haploidentical BMT with high-dose posttransplantation cy‐
clophosphamide: effect of HLA disparity on outcome. Biol. Bone Marrow Transplant.
2010; 16: 482-489. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998606/ (accessed
20 September 2012).
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
25
[40] Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, et al. Non‐
myeloblative HLA-haploidentical bone marrow transplantation with higth dose, post
transplantation cyclophosphamide. 2011 Pediatric Reports 2011;3:2-15. http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC3206539/ (accessed 01 September 2012).
[41] Liao C, Wu J. Y, et al, Indiscernible benefit of high-resolution HLA typing in improv‐
ing long-term clinical outcome of unrelated umbilical cord blood transplant. Bone
Marrow Transplantation 2007; 40: 201-8. http://www.nature.com/bmt/journal/v40/n3/
full/1705711a.html (accessed 02 September 2012).
[42] Kanda J, Ichinohe T, Kato S, Uchida N, Terakura S, Fukuda T et al, Unrelated cord
blood transplantation vs related transplantation with HLA 1-antgen mismatch in the
graft-versus-host direction. Leukemia 2012; 203. http://www.nature.com/leu/journal/
vaop/ncurrent/full/leu2012203a.html (accessed 03 September 2012).
[43] Rodrigues C. A, Pereira N. F, et. al, Umbilical Cord blood transplantation. Ver. Bras.
Hematol. Hemoter. 2010.
[44] Atsuta Y, Morishima Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S et.
al, Comparison of unrelated cord blood transplantation and HLA-mismatched unre‐
lated bone marrow transplantation for adults with leukemia. Biol. Blood Marrow
Transplant 2012;18:780-7. http://www.bbmt.org/article/S1083-8791(11)00411-3/
abstract (accessed 20 August 2012).
[45] Sang Yi E, Lee SH. Hematopoietic stem cell in children with acute leukemia: similar
outcomes in recipients of umbilical cord blood versus marrow or peripheral blood
stem cells from related or unrelated donors. Korean Journal Pediatric 2012;55:93-9.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315625/ (accessed 03 September
2012).
[46] Rocha V, John MD. Graft-Versus-Host Disease in Children who have received a cord
blood or bone marrow transplant from an HLA-identical sibling. N. Engl. J. Med
2000; 342:1846-54. http://www.nejm.org/doi/full/10.1056/NEJM200006223422501 (ac‐
cessed 20 August 2012).
[47] Wen S. H, Lai M. J, Yang K. L. Human Leukocyte antigen-A, -B, -DRB1 haplotypes of
cord blood units in the Tzu Chi Taiwan Cord Blood Bank. Human immunology.
2008; 69: 430-6. http://www.sciencedirect.com/science/article/pii/ (accessed 20 Sep‐
tember 2012).
[48] Brown J, Poles A, Brown CJ, Contreras M, Navarrete CV. HLA-A, -B, and DR antigen
frequencies of the London Cord Blood Bank units differ from those found in estab‐
lished bone marrow donor registries. Bone Marrow Transplan. 2000; 25: 475-81.
http://www.nature.com/bmt/journal/v25/n5/full/1702197a.html (accessed 20 Septem‐
ber 2012).
[49] Trinchieri G. 1989. Biology of natural killer cells. Adv. Immunol. 1989. 47:187–376.
Innovations in Stem Cell Transplantation26
[50] Cerwenka A, Lanier LL .Natural killer cells, viruses and cancer. Nat Rev Immunol
2001;1:41–9. http://www.uiowa.edu/~immuno/classMaterial/Advanced%20Topics
%202004/Session%2010,%20Sept%2027/Cerwenka,%20Lanier.pdf (accessed 03 may
2012)
[51] Caligiuri MA. Human natural killer cells. Blood 2008;112:461–9.http://bloodjour‐
nal.hematologylibrary.org/content/112/3/461.short (accessed 02 may 2012)
[52] Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, et al. Innate
immune surveillance of spontaneous B cell lymphomas by natural killer cells and
gammadelta T cells. J Exp Med 2004;199:879– 84 http://jem.rupress.org/content/
199/6/879.short (accessed 02 may 2012)
[53] Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia
2008; 22: 249–57.http://www.nature.com/leu/journal/v22/n2/full/2405040a.html (ac‐
cessed 02 may 2012)
[54] Kulkarni S, Martin MP, Carrington M. The yin and yang of HLA and KIR in human
disease. Semin Immunol 2008;20:343–52. http://www.sciencedirect.com/science/arti‐
cle/pii/S1044532308000523 (accessed 01 April 2009)
[55] Dupont B, Hsu KC. Inhibitory killer Ig-like receptor genes and human leukocyte an‐
tigen class I ligands in haematopoietic stem cell transplantation. Curr Opin Immunol
2004;16:634–43.http://www.sciencedirect.com/science/article/pii/S0952791504001190
(accessed 01 April 2009)
[56] Barao I, Murphy W. The immunobiology of natural killer cells and bone marrow al‐
lograft rejection. Biol Blood Marrow Transplant 2003; 9:727-41.http://www.science‐
direct.com/science/article/pii/S1083879103003343 (accessed 23 january 2008)
[57] Thielens, A; Vivier E; Romagne F. NK cell MHC class I specific receptors (KIR): from
biology to clinical intervention. Current Opinion in Immunology 2012; 24:239–
45.http://www.sciencedirect.com/science/article/pii/S0952791512000039 (accessed 02
may 2012)
[58] Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells
with specificity for mouse Moloney leukemia cells. Specificity and distribution ac‐
cording to genotype. Eur J Immunol 1975;(5):112–7. http://
onlinelibrary.wiley.com/doi/10.1002/eji.1830050208/abstract;jsessio‐
nid=682FA874FA648EE08CFD6607AE91874E.d01t02 (accessed 15 january 2006)
[59] Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell
subsets. Trends Immunol 2001;22:633–40.http://www.sciencedirect.com/science/arti‐
cle/pii/S1471490601020609 (accessed 02 may 2012)
[60] Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, et
al. Human diversity in killer cell inhibitory receptor. Genes Immun 1997;7:753–
63.http://www.sciencedirect.com/science/article/pii/S1074761300803945 (accessed 09
February 2006)
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
27
[61] Martin AM, Freitas EM, Witt CS, Christiansen FT. The genomic organization and
evolution of the natural killer immunoglobulin-like receptor (KIR) gene cluster. Im‐
munogenetics 2000;51:268 – 80. http://www.springerlink.com/content/100517/ (ac‐
cessed 09 February 2006)
[62] Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 transduces signals
into human NK cells through association with the Fc receptor gamma protein. J Im‐
munol 2005; 174:3859–63 http://www.jimmunol.org/content/174/7/3859.long (ac‐
cessed 09 February 2006)
[63] Hsu KC,Liu XR, Selvakumar A, Mickelson E, O’Reilly RJ, Dupont B. Killer Ig-like re‐
ceptor haplotype analysis by gene content: evidence for genomic diversity with a
minimum of six basic framework haplotypes, each with multiple subsets. J Immunol
2002;169:5118 –129. http://www.jimmunol.org/content/169/9/5118.long (accessed 02
may 2012)
[64] Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and
functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C al‐
lotype recognition. J Immunol 1998;161:571–7.http://www.jimmunol.org/content/
161/2/571.long (accessed 05 July 2012)
[65] Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibito‐
ry ligand that det ermines dominant resistance to lysis by NK1- and NK2-specific
natural killer cells. Proc Natl Acad Sci U S A 1993;90:12000- 4.http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC48113/ (accessed 05 July 2012)
[66] Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer cell inhibitory
receptors specific for HLA-C and HLA-B identified by direct binding and by func‐
tional transfer. Immunity 1995;3:8 01-9.http://www.sciencedirect.com/science/
article/pii/107476139 5900691 (accessed 05 July 2012)
[67] Thananchai H, Gillespie G, Ma rtin MP, Bashirova A, Yawata N, Yawata M, et al.
Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1
and HLA- A and HLA-B. J Immunol 2007; 178:33-7.http://www.jimmunol.org/
content/178/1/ 33.long (accessed 02 may 2012)
[68] Foley BA, De Santis D, Van Beelen E, Lathbury LJ, Christiansen FT, Witt CS. The re‐
activity of Bw4-positive HLA-B and HLA-A alleles with KIR3DL1: implications for
pati ent and donor suitability for haploidentical stem cell transplants. Blood 2008;
112:435-443.http://bloodjournal.hematologylibrary.org/content/112/2/435.full (ac‐
cessed 25 Jan uary 2012)
[69] Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A. Human leukocyte antigens
A23, A24 and A32 but not A25 are ligands for KIR3DL1. Blood 2008; 112:708-1
0.http://bloodjournal.hematologylibrary.org/content/112/3/708.long (accessed 25 Jan‐
uary 2012)
[70] O’Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM.
Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immu‐
Innovations in Stem Cell Transplantation28
nol 2007;178:235-41. http://www.jimmunol.org/content/178/1/235.long (accessed 1 7
April 2010)
[71] Muller CA, Engler-Blum G, Gekeler V, Steiert I, Weiss E, Schmidt H. Genetic and se‐
rological heterogeneity of the supertypic HLA-B locus specificities HLA-Bw4 and-
Bw6 lmmunogenetics 1989; 30: 200-7. http://www.springerlink.com/content/
p43708943411367 7/ (accessed 05 August 2012)
[72] Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S, et al. Role of ami‐
no acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4
molecules. Eur J Immunol 1997;27, 3095–9. http://onlinelibrary.wiley.com/doi/
10.1002/eji.1830271203/abstract (accessed 25 January 2012)
[73] Parham, P. MHC class I molecules and KIRs in human history, health and survival.
Nat Rev Immunol, 2005; 5(3):201-214. (http://www.ncbi.nlm.nih.gov/pubmed/
15719024 (accessed 17 August 2009)
[74] Katz G, Markel G, Mizrahi S, Arnon TI, Mandelboim O. Recognition of HLA-Cw4
but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain
short tail number 4. J Immunol 2001;166:7260-7267.(accessed 05 August 2012)
[75] Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. Viral evasion of nat‐
ural killer cells. Nat Immunol 2002;3:1006 –12.
[76] Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, et al. Role of
the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition
of leukemic cells by Natural Killer cells. Cancer Immunol Immunother 2009;58(6):
855–65.http://www.springerlink.com/content/v5158n27t2216718/ (accessed 05 August
2012)
[77] Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient
lymphoma variants suggests alternative immune defense strategy. Nature
1986;319:675–8. http://www.nature.com/nature/journal/v319/n6055/abs/
319675a0.html (accessed 05 August 2012)
[78] Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell
recognition. Immunol Today 1990;11:237–44. http://www.ncbi.nlm.nih.gov/pubmed/
2201309 (accessed 05 August 2012)
[79] Moretta L, Ciccone E, Moretta A, Hoglund P, Ohlen C, Karre K. Allorecognition by
NK cells: nonself or no self? Immunol Today 1992;13:300–6. http://
www.ncbi.nlm.nih.gov/pubmed/1380815 (accessed 05 August 2012)
[80] Van Bergen J, Thompson A, Retiere C, Trowsdale J, Koning F. Cutting edge: killer Ig-
like receptors mediate "missing self" recognition in vivo. J Immunol 2009;182(5):
2569–72.http://www.ncbi.nlm.nih.gov/pubmed/19234149 (accessed 05 August 2012)
[81] Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allor‐
ecognition of missing self in allogeneic hematopoietic transplantation: a tool for im‐
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
29
munotherapy of leukemia. Curr Opin Immunol 2009; 21:525–30.http://
www.ncbi.nlm.nih.gov/pubmed/19717293 (accessed 05 August 2012)
[82] Parham P: Taking license with natural killer cell maturation and repertoire develop‐
ment. Immunol Rev 2006; 214:155-160. http://www.ncbi.nlm.nih.gov/pubmed/
17100883 (accessed 05 August 2012)
[83] Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-toler‐
ance and maximal responses to diseased target cells. Immunol Rev 2008; 224:85-97.
http://www.ncbi.nlm.nih.gov/pubmed/18759922 (accessed 05 August 2012)
[84] Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P.
MHC class I-specific inhibitory receptors and their ligands structure diverse human
NK-cell repertoires toward a balance of missing self-response. Blood 2008;
112:2369-80. http://www.ncbi.nlm.nih.gov/pubmed/18583565 (accessed 05 August
2012)
[85] Jonsson AH, Yokoyama WM. Natural killer cell tolerance licensing and other mecha‐
nisms. Adv Immunol 2009; 101:27-79. http://www.ncbi.nlm.nih.gov/pubmed/
19231592 (accessed 05 August 2012)
[86] Brodin P, Karre K, Hoglund P. NK cell education: not an on–off switch but a tunable
rheostat. Trends Immunol 2009; 30:143-9. http://www.ncbi.nlm.nih.gov/pubmed/
19282243 (accessed 05 August 2012)
[87] Pegram HJ, Ritchie DS, Smyth MJ, Wiernik A, Prince HM, Darcy PK et al. Alloreac‐
tive natural killer cells in hematopoietic stem cell transplantation leukemia Research
2011;35:14–21.http://www.ncbi.nlm.nih.gov/pubmed/20719383 (accessed 05 August
2012)
[88] Kook H, Goldman F, Padley D, Giller R, Rumelhart S, Holida M, et al. Reconstruction
of the immune system after unrelated or partially matched T-cell-depleted bone mar‐
row transplantation in children: immunophenotypic analysis and factors affecting
the speed of recovery. Blood 1996;88:1089–97.http://www.ncbi.nlm.nih.gov/pubmed/
8704219 (accessed 05 August 2012)
[89] Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effective‐
ness of donor natural killer cell alloreactivity in mismatched hematopoietic trans‐
plants. Science 2002; 295:2097–100.http://www.ncbi.nlm.nih.gov/pubmed/11896281
(accessed 05 August 2012)
[90] Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-
cell transplantation: a phase II study in patients with acute leukemia at high risk of
relapse. J Clin Oncol 2005;23:3447–54. http://www.ncbi.nlm.nih.gov/pubmed/
15753458 (accessed 05 August 2012)
[91] Pende D, Marcenaro S, Falco M Martini S, Bernardo ME, Montagna D, et al. Anti-leu‐
kemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical
HSCT for pediatric patients: evaluation of the functional role of activating KIR and
Innovations in Stem Cell Transplantation30
re-definition of inhibitory KIR specificity. Blood 2009; 113:3119–29.http://
www.ncbi.nlm.nih.gov/pubmed/18945967 (accessed 05 August 2012)
[92] Sun JY, Gaidulis L, Miller MM, Goto RM, Rodriguez R, Forman SJ et al. Development
of a multiplex PCR-SSP method for Killer-cell immunoglobulin-like receptor geno‐
typing. Tissue Antigens 2004;64:462–8.http://www.ncbi.nlm.nih.gov/pubmed/
15361123 (accessed 05 August 2012)
[93] Ciccone E, Pende D, Vitale M, Nanni L, Di Donato C, Bottino C et al. Self class I mole‐
cules protect normal cells from lysis mediated by autologous natural killer Cells. Eur
J Immunol. 1994;24(4):1003-6. http://www.ncbi.nlm.nih.gov/pubmed/8149950 (ac‐
cessed 05 August 2012)
[94] Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of anti‐
leukemia effects of allogeneic NK cells. J Immunol 2004;172(1):644–50. http://
www.ncbi.nlm.nih.gov/pubmed/14688377 (accessed 05 August 2012)
[95] Stern M, Ruggeri L, Mancusi A, Bernardo ME, De Angelis C, Bucher C, et al. Survival
after T cell-depleted haploidentical stem cell transplantation is improved using the
mother as donor. Blood 2008; 112:2990-5 http://www.ncbi.nlm.nih.gov/pubmed/
18492955 (accessed 05 August 2012)
[96] Fischer JC; Kobbe G; Enczmann J; Haas R; Uhrberg M. The impact of HLA-C match‐
ing depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell
transplantation Immunogenetics 2012 Aug 26. [Epub ahead of print] http://
www.ncbi.nlm.nih.gov/pubmed/22923051 (accessed 05 September 2012)
[97] Kärre K. Immunology. A perfect mismatch. Science. 2002;295 (5562):2029-31. Com‐
ment on: Science. 2002;295(5562):2097- 100; Science. 2002;295(5562):2094-7.http://
www.sciencemag.org/content/295/5562/2029 (accessed 10 April 2012)
[98] Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Mar‐
row transplantation from related donors other than HLA-identical siblings. N Engl J
Med. 1985;313(13):765-71.http://www.ncbi.nlm.nih.gov/pubmed/3897863 (accessed
10 April 2012)
[99] Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural
killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.
Blood 1999;94:333–9. http://bloodjournal.hematologylibrary.org/content/94/1/333.full
(accessed 10 April 2012)
[100] Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al. Donor natural
killer cell allorecognition of missing self in haploidentical hematopoietic transplanta‐
tion for acute myeloid leukemia: challenging its predictive value. Blood
2007;110:433–440. http://www.ncbi.nlm.nih.gov/pubmed/17371948 (accessed 05 Au‐
gust 2012)
[101] Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention
of graft versus host disease by inactivation of host antigen- presenting cells. Science
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
31
1999;285:412–5. http://www.sciencemag.org/content/285/5426/412.abstract (accessed
05 August 2012)
[102] RuggeriL, Mancusi A, Burchielli E, Perruccio K, Aversa F, Mertelli MF. Natural killer
cell recognition of missing self and haploidentical hematopoietic transplantation.
Seminars in Cancer Biology 2006; (16):404–11. http://www.sciencedirect.com/science/
article/pii/S1044579X06000599 (accessed 05 August 2012)
[103] Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, et al.
Pediatric Diseases and Acute Leukemia Working Parties of the European Group for
Blood and Marrow Transplantation (EBMT). Results and factors influencing outcome
after fully haploidentical hematopoietic stem cell transplantation in children with
very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on be‐
half of the Acute Leukemia and Pediatric Disease Working Parties of the European
Blood and Marrow Transplant group Blood. 2010; 29;115(17):3437-46. http://blood‐
journal.hematologylibrary.org/content/115/17/3437.short (accessed 05 August 2012)
[104] Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A. Natural killer cells
expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic
cells: implications in haploidentical HSCT. Blood 2011; 117(16):4284-92. http://blood‐
journal.hematologylibrary.org/content/117/16/4284.short (accessed 23 July 2012)
[105] Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved sur‐
vival with inhibitory Killer Immunoglobulin Receptor (KIR) gene mismatches and
KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow
transplantation Biol Blood Marrow Transplant. 2010; 16(4): 533–42.http://www.scien‐
cedirect.com/science/article/pii/S1083879109005825 (accessed 23 July 2012)
[106] Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, et al. A survey of fully
haploidentical hematopoietic stem cell transplantation in adults with high-risk acute
leukemia: a risk factor analysis of outcomes for patients in remission at transplanta‐
tion Blood, 2008;112(9): 3574-81.http://bloodjournal.hematologylibrary.org/content/
112/9/3574.short (accessed 23 July 2012)
[107] Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, et al. The benefi‐
cial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mis‐
matched stem cell allografts may be masked by residual donor-alloreactive T cells
causing GVHD Tissue Antigens. 2004;63(3):204-11.http://onlinelibrary.wiley.com/doi/
10.1111/j.0001-2815.2004.00182.x/full (accessed 23 July 2012)
[108] Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival
advantage with KIR ligand incompatibility in hematopoietic stem cell transplanta‐
tion from unrelated donors Blood, 2003; 102(3):814-9.http://bloodjournal.hematology‐
library.org/content/102/3/814.short (accessed 23 July 2012)
[109] Beelen DH, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, et al.
Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility en‐
hances the long-term antileukemic effect of unmodified allogeneic hematopoietic
Innovations in Stem Cell Transplantation32
stem cell transplantation in patients with myeloid leukemias. Blood, 2005;105(6):
2594-600.http://bloodjournal.hematologylibrary.org/content/105/6/2594.short (ac‐
cessed 23 July 2012)
[110] Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont, B, Bignon JD et al. KIR Li‐
gands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Trans‐
plantation for Hematologic Malignancy. Biology of Blood and Marrow
Transplantation 2006;12:828-836.http://www.sciencedirect.com/science/article/pii/
S108387910600317X (accessed 23 July 2012)
[111] Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS et al. Rapid natural
killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell
transplantation in patients with myeloid leukemias but not with acute lymphoblastic
leukemia. Leukemia 2007;21:2145–52.http://www.nature.com/leu/
journal/v21/n10/abs/2404892a.html (accessed 23 July 2012)
[112] Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT et al. Donors
with group B KIR haplotypes improve relapse-free survival after unrelated hemato‐
poietic cell transplantation for acute myelogenous leukemia.Blood. 2009;113(3):
726-32. http://www.ncbi.nlm.nih.gov/pubmed/18945962 (accessed 23 July 2012)
[113] Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT et al. Donor se‐
lection for natural killer cell receptor genes leads to superior survival after unrelated
transplantation for acute myelogenous leukemia Blood. 2009;113(3):726-32.http://
bloodjournal.hematologylibrary.org/content/116/14/2411.short (accessed 23 July
2012)
[114] Tomblyn M, Young JH, Haagenson MD, Klein JP, Trachtenberg EA, Storek J, et al.
Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Trans‐
plantation from Donors with an Activating KIR Genotype Biol Blood Marrow Trans‐
plant. 2010;16(8):1155-61.http://www.sciencedirect.com/science/article/pii/
S1083879110000972 (accessed 23 July 2012)
[115] Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, et al. Donor acti‐
vating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic
hematopoietic stem cell transplantation. Blood 2010;115(15):3162-5.http://bloodjour‐
nal.hematologylibrary.org/content/115/15/3162.short (accessed 23 July 2012)
[116] Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M et al.
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1.
N Engl J Med. 2012;367(9):805-16.http://www.nejm.org/doi/full/10.1056/
NEJMoa1200503 (accessed 23 July 2012)
[117] Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural
killer cell receptor genotype protects against leukemic relapse after related HLA-
identical hematopoietic stem cell transplantation. Leukemia. 2005;19(8):
1446-51.http://www.nature.com/leu/journal/v19/n8/abs/2403839a.html (accessed 23
July 2012)
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
33
[118] Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, et al. Ac‐
tivating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-
host disease and affect survival after allogeneic hematopoietic stem cell
transplantation Eur J Haematol. 2009;83(4):343-56.http://onlinelibrary.wiley.com/doi/
10.1111/j.1600-0609.2009.01280.x/full (accessed 23 July 2012)
[119] Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, et al. Low num‐
ber of donor activating killer immunoglobulin-like receptors (KIR) genes but not
KIR-ligand mismatch prevents relapse and improves disease-free sur- vival in leuke‐
mia patients after in vivo T-cell depleted unrelated stem cell transplantation. Trans‐
plantation 2006;82(8):1024–30.http://journals.lww.com/transplantjournal/Abstract/
2006/10270/Low_Number_of_Donor_Activating_Killer.4.aspx (accessed 23 July 2012)
[120] Davies SM, Ruggieri L, For TD, Wagner JE, Weisdorf DJ, Miller JS, et al. Evaluation
of KIR ligand incompatibility in mismatched unrelated donor hematopoietic trans‐
plants Blood, 2002;100(10):3825-7. http://bloodjournal.hematologylibrary.org/content/
100/10/3825.short (accessed 23 July 2012)
[121] Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F, et al. Relevance of
KIR Gene Polymorphisms in Bone Marrow Transplantation Outcome Hum Immu‐
nology 2002;63, 271–280. http://www.sciencedirect.com/science/article/pii/
S0198885902003737 (accessed 23 July 2012)
[122] Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al.The effect
of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a
report from the center for international blood and marrow transplant research, the
European blood and marrow transplant registry, and the Dutch registry. Biol Blood
Marrow Transplant. 2006;12:876–84. http://www.ncbi.nlm.nih.gov/pubmed/16864058
(accessed 23 July 2012)
[123] Loiseau P, Busson M, Balere M-L, Dormoy A, Bignon J-D, Gagne K et al. HLA Asso‐
ciation with Hematopoietic Stem Cell Transplantation Outcome: The Number of Mis‐
matches at HLA-A, -B, -C, -DRB1, or -DQB1 Is Strongly Associated with Overall
Survival. Biol Blood Marrow Transplant 2007;13:965-974 http://
www.ncbi.nlm.nih.gov/pubmed/17640601 (accessed 23 July 2012)
[124] Schaffer M, Malmberg KJ, Ringden O, Ljunggren HG, Remberger M. Increased infec‐
tion-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic
stem-cell transplantation. Transplantation 2004;78(7):1081–5.http://
www.ncbi.nlm.nih.gov/pubmed/15480179 (accessed 23 July 2012)
[125] Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G. Role
of KIR ligand incompatibility in hematopoietic stem cell transplantation using unre‐
lated donors. Blood 2004;103(7):2860–1, author reply 2862. http://bloodjournal.hema‐
tologylibrary.org/content/103/7/2860.short (accessed 23 July 2012)
[126] Santis DD, Bishara A, Witt
CS, Nagler A, Brautbar C, Slavin
Innovations in Stem Cell Transplantation34
S, et al. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like recep‐
tors both influence outcome of mismatched unrelated donor bone marrow trans‐
plants.Tissue Antigens 2005; 65:519–28.http://onlinelibrary.wiley.com/doi/10.1111/j.
1399-0039.2005.00396.x/abstract;jsessio‐
nid=E8C4CEAE2AAE53DE255675692DAD0D7B.d04t03?deniedAccessCustomised‐
Message=&userIsAuthenticated=false (accessed 23 July 2012)
[127] Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF. The
impact of donor KIR and patient HLA-C genotypes on outcome following HLA-
identical sibling hematopoietic stem cell transplantation for myeloid leukemia Blood
2004; 103(4):1521-6. http://bloodjournal.hematologylibrary.org/content/
103/4/1521.short (accessed 23 July 2012)
[128] Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al Improved
outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute
myelogenous leukemia predicted by KIR and HLA genotypes Blood 2005;105(12):
4878-84. http://bloodjournal.hematologylibrary.org/content/105/12/4878.short (ac‐
cessed 23 July 2012)
[129] Clausen J, Wolf D, Petzer AL,
Gunsilius E, Schumacher P, Kircher B, et al. Impact of natural killer cell dose and do‐
nor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following
human leucocyte antigen-identical haematopoietic stem cell transplantation. Clinical
and Experimental Immunology 2007;148: 520–8.http://onlinelibrary.wiley.com/doi/
10.1111/j.1365-2249.2007.03360.x/full (accessed 23 July 2012)
[130] Stringaris K, Adams S, Uribe M, Eniafe R, Wu CO, Savani BN, et al. Donor KIR
Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Re‐
lapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leu‐
kemia but Not Other Hematologic Malignancies Biol Blood Marrow Transplant
2010;16(9):1257-64. http://www.bbmt.org/article/S1083-8791(10)00109-6/abstract (ac‐
cessed 23 July 2012)
[131] Chen C, Busson M, Rocha V, Appert M-L, Lepage V, Dulphy N et al. Activating KIR
genes are associated with CMV reactivation and survival after non-T-cell depleted
HLA-identical sibling bone marrow transplantation for malignant disorders. Bone
Marrow Transplant 2006;38:437–444. http://www.nature.com/bmt/
journal/v38/n6/abs/1705468a.html (accessed 23 July 2012)
[132] Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on
the rate of cytomegalovirus reactivation following T-cell replete stem cell transplan‐
tation. Blood 2006;107:1230–2. http://bloodjournal.hematologylibrary.org/content/
107/3/1230.abstract (accessed 23 July 2012)
[133] Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF, et al. The effect of
single and combined activating KIR genotypes on CMV infection and immunity after
hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(3):315–25.
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
35
http://www.sciencedirect.com/science/article/pii/S1083879108005806 (accessed 23 Ju‐
ly 2012)
[134] McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P. Donor-
Recipient Combinations of Group A and B KIR Haplotypes and HLA Class I Ligand
Affect the Outcome of HLA-Matched, Sibling Donor Hematopoietic Cell Transplan‐
tation Hum Immunol. 2007; 68(5): 309–23. http://www.sciencedirect.com/science/arti‐
cle/pii/S0198885907000286 (accessed 23 July 2012)
[135] Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M, et al. Surviv‐
al of AML patients receiving HLA-matched sibling donor allogeneic bone marrow
transplantation correlates with HLA-Cw ligand groups
for killer immunoglobulin-like receptors. Bone Marrow Transplantation 2007;39:417–
24. http://www.nature.com/bmt/journal/v39/n7/abs/1705609a.html (accessed 23 July
2012)
[136] Gabriel IH, Sergeant R, Szydlo R, Apperley JF, Lavallade H, Alsuliman A, et al. Inter‐
action between KIR3DS1 and HLA-Bw4 predicts for progression-free survival fol‐
lowing autologous stem cell transplantation in patients with multiple myeloma.
Blood 2010;116(12):2033-9.http://bloodjournal.hematologylibrary.org/content/
116/12/2033.short (accessed 23 July 2012)
[137] Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY et al. KIR and HLA
genotypes are associated with disease progression and survival following autologous
hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer
Res. 2009;15(23): 7330-4. http://clincancerres.aacrjournals.org/content/
15/23/7330.short (accessed 23 July 2012)
[138] Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory
KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell trans‐
plantation for solid tumour and lymphoma. Br J Cancer. 2007;97(4):539-42. http://
www.nature.com/bjc/journal/v97/n4/abs/6603913a.html (accessed 23 July 2012)
[139] Stern M, Paulussen M, Rischewski J, Tichelli A, Gratwohl A. Missing ligand model in
autologous stem cell transplantation. Br J Cancer. 2008;98(4):852-3. http://
www.nature.com/bjc/journal/v98/n4/full/6604153a.html (accessed 23 July 2012)
[140] Willemze R, Arrais Rodrigues C, Labopin M, Sanz G, Michel G, Socié G et al KIR-
ligand incompatibility in the graft-versus-host direction improves outcomes after
umbilical cord blood transplantation for acute leukemiaKIR-ligand incompatibility
and umbilical cord blood stem cell transplantation Leukemia 2009; 23, 492-500 http://
www.nature.com/leu/journal/v23/n3/full/leu2008365a.html (accessed 23 July 2012)
[141] Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN et al. Nega‐
tive effect of KIR alloreactivity in recipients of umbilical cord blood transplant de‐
pends on transplantation conditioning intensity. Blood 2009;113:5628–34. http://
bloodjournal.hematologylibrary.org/content/113/22/5628.short (accessed 23 July
2012)
Innovations in Stem Cell Transplantation36
[142] Velardi A. Natural killer cell alloreactivity 10 years later. Curr Opin Hematol 2012,
19:000 – 000 DOI:10.1097/MOH.0b013e3283590395 http://www.ncbi.nlm.nih.gov/
pubmed/22954728 (accessed 25 September 2012)
[143] Visentainer JE, Lieber SR, Persoli LB, Vigorito AC, Aranha FJ, Eid KA, et al. Serum
cytokine levels and acute graft-versus-host disease after HLA-identical hematopoiet‐
ic stem cell transplantation. Experimental Hematology 2003;31:703-10. http://
www.exphem.org/article/S0301-472X(03)00264-9/abstract (accessed 20 September
2012).
[144] Ju XP, Xu B, Xiao ZP, Li JY, Chen L, Lu S et al. Cytokine expression during acute
graft-versus-host disease after allogeneic peripheral stem cell transplantation. Bone
Marrow Transplantation 2005;35:1179-1186. http://www.nature.com/bmt/
journal/v35/n12/full/1704972a.html (accessed 20 August 2012).
[145] Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Djckmeiss E, Vindeloy LL. Cyto‐
kine gene expression in peripheral blood mononuclear cells and alloreactivity in
hematopoietic cell transplantation with nonmyeloblative conditioning.. Biol. Blood
Marrow Transplantation 2006;12:48-60. http://www.bbmt.org/article/
S1083-8791(05)00628-2/abstract (accessed 21 August 2012).
[146] Vizoni S, Lieber S, Souza CA, Sell AM, Visentainer JL. Role of cytokines in the immu‐
nophatogenesis of Graft-versus-host disease. Revista Brasileira de Hematologia e He‐
moterapia 2008;30:142-152. http://www.scielo.br/scielo.php?
script=sci_arttext&pid=S1516-84842008000200013 (accessed 30 September 2012).
[147] Espinoza JL, Takami A, Onizuka M, Kawase T, Sao H, Akiyama H, et al. A single nu‐
cleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD
after HLA-matched unrelated BMT. Bone Marrow Transplantation
2011;46:1455-1463. http://www.nature.com/bmt/journal/v46/n11/full/
bmt2010325a.html (accessed 30 September 2012).
[148] Takabayashi M, Kanamori H, Takasaki H, Yamaji S, Koharazawa H, Taguchi J et al.
A possible association between the presence of interleukin-4 secreting cells and a re‐
duction in the risk of acute graft-versus-host disease. Experimental Hematology
2005;33: 251-257. http://www.exphem.org/article/S0301-472X(04)00358-3/abstract (ac‐
cessed 12 August 2012).
[149] Goyal RK, Lin Y, Schultz KR, Ferrell RE, Kim Y, Fairfull L, et al. Tumor necrosis fac‐
tor-alpha gene polymorphisms are associated with severity of acute graft-versus-host
disease following matched unrelated donor bone marrow transplantation in chil‐
dren: a Pediatric Blood and Marrow Transplant Consortium study. Biology of Blood
and Marrow Transplantation 2010;16:927-936. http://www.bbmt.org/article/
S1083-8791(10)00025-X/abstract (accessed 13 September 2012).
[150] Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian ma‐
jor histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1994;
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
37
91:6259-63. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC44180/ (accessed 24 Au‐
gust 2012).
[151] Leelayuwat C, Townend DC, Degli-Esposti MA, Abraham LJ, Dawkins RL. A new
polymorphic and multicopy MHC gene family related to nonmammalian class I. Im‐
munogenetics 1994; 40: 339–51. http://www.ncbi.nlm.nih.gov/pubmed?term=A
%20new%20polymorphic%20and%20multicopy%20MHC%20gene%20family%20re‐
lated%20to%20nonmammalian%20class%20I (accessed 29 September 2012).
[152] Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothe‐
lial cells, fibroblasts, keratinocytes, and monocytes. Human Immunol 1999;
60:323-330. http://www.sciencedirect.com/science/article/pii/S0198885998001281 (ac‐
cessed 29 September 2012).
[153] Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated
human major histocompatibility complex class I gene expressed in gastrointestinal
epithelium. Proc Natl Acad Sci U S A 1996; 93: 12445–50. http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC38011/ (accessed 29 September 2012).
[154] Zwirner NW, Fernandez-Vina MA, Stastny P. MICA, a new polymorphic HLA-relat‐
ed antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes.
Immunogenetics 1998; 47: 139–48. http://www.springerlink.com/content/100517/ (ac‐
cessed 30 August 2012).
[155] Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor
for stress-inducible MICA. Science 1999; 285: 727–9. http://www.sciencemag.org/
content/285/5428/727.long (accessed 23 August 2012).
[156] Zwirner NW, Marcos CY, Mirbaha F, Zou Y, Stastny P. Identification of MICA as a
new polymorphic alloantigen recognized by antibodies in sera of organ transplant
recipients. Hum Immunol 2000;61:917–24. http://www.sciencedirect.com/science/arti‐
cle/pii/S0198885900001622 (accessed 20 September 2012).
[157] Mizutani K, Terasaki PI, Shih RN, Pei R, Ozawa M, Lee J. Frequency of MIC antibody
in rejected renal transplant patients without HLA antibody. Hum Immunol.
2006;67(3):223-229. http://www.sciencedirect.com/science/article/pii/
S0198885906000280 (accessed 13 August 2012).
[158] Hankey KG, Drachenberg CB, Papadimitriou JC, Klassen DK, Philosophe B, Bartlett
ST. MIC expression in renal and pancreatic allografts. Transplantation
2002;73:304-306. http://journals.lww.com/transplantjournal/pages/articleviewer.aspx?
year=2002&issue=01270&article=00029&type=abstract (accessed 23 September 2012).
[159] Narayan S, Tsai EW, Zhang Q, Wallace WD, Reed EF, Ettenger RB. Acute rejection
associated with donor specific anti-MICA antibody in a highly sensitized pediatric
renal transplant recipient. Pediatric Transplantation. 2011;15(1): E1-7. http://onlineli‐
brary.wiley.com/doi/10.1111/j.1399-3046.2010.01407.x/abstract (accessed 12 Septem‐
ber 2012).
Innovations in Stem Cell Transplantation38
[160] Panigrahi A, Gupta N, Siddiqui JA, Margoob A, Bhowmik D, Guleria S. Post trans‐
plant development of MICA and anti-HLA antibodies is associated with acute rejec‐
tion episodes and renal allograft loss. Hum Immunol 2007; 68:362-7. http://
www.sciencedirect.com/science/article/pii/S0198885907000195 (accessed 12 Septem‐
ber 2012).
[161] Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clini‐
cal transplantation
Curr Opi Immunol 2008; 20:607–13. http://www.sciencedirect.com/science/article/pii/
S0952791508001234 (accessed 30 Aigust 2012).
[162] Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA
and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-15.
http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2006.01644.x/abstract (accesses
13 September 2012).
[163] Stastny P. Introduction: MICA/MICB in innate immunity, adaptive immunity, auto‐
immunity, cancer, and in the immune response to transplants. Hum Immunol 2006;
67:141-144. http://www.sciencedirect.com/science/article/pii/S0198885906000401 (ac‐
cessed 24 September 2012).
[164] Parmar S, Del lima M, Zou Y, Patah PA, Liu P, Cano P et al. Donor-recipient mis‐
matches in MHC class I chain-related gene A in unrelated donor transplantation lead
to increased incidence of acute graft-versus-host disease. Blood 2009;114:2884–7.
http://bloodjournal.hematologylibrary.org/content/114/14/2884.long (accessed 20
September 2012).
[165] Kitcharoen, K, Witt CS, Romphruk AV, Christiansen FT, Leelayuwat. MICA, MICB,
and MHC beta block matching in bone marrow transplantation: relevance to trans‐
plantation outcome. Hum Immunol 2006;67:238–46. http://www.sciencedirect.com/
science/article/pii/S0198885906000334 (accessed 23 August 2012).
[166] Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK et al. Interactions of human
NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein
family. Immunogenetics 2001;53(4):279-87. http://www.springerlink.com/content/
100517/ (accessed 12 August 2012).
[167] Boukouaci W, Busson M, Peffault de Latour R, Rocha V, Suberbielle C, Bengoufa D,
et al. MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of
chronic graft-versus-host disease. Blood 2009;114(25):5216-24. http://bloodjour‐
nal.hematologylibrary.org/content/114/25/5216.long (accessed 12 August 2012).
[168] Goulmy E, Termijtelen A, Bradley BA, van Rood JJ. Alloimmunity to human H-Y.
Lancet 1206, 1976. http://www.sciencedirect.com/science/article/pii/
S014067367691727X (accessed 24 August 2012).
[169] Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol.
1996;8(1):75-81.
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
39
[170] Goulmy E Minor Histocompatibility Antigens: from Transplantation Problems to
Therapy
of Cancer. Human Immunology 2006; 67, 433–438 (2006). http://www.sciencedir‐
ect.com/science/article/pii/S0198885906000528 (accessed 24 August 2012).
[171] Warren EH, Zhang XC, Li S, Fan W, Storer BE, Chien JW, et al. Effect of MHC and
non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.
Blood. 2012; Aug 2. [Epub ahead of print]. http://bloodjournal.hematologyli‐
brary.org/content/120/14/2796.long (accessed 24 September 2012).
[172] Spierings E, Drabbels J, Hendriks M, Pool J, Spruyt-Gerritse M, et al. A uniform ge‐
nomic minor histocompatibility antigen typing methodology and database designed
to facilitate clinical applications. PloS One. 2006;1(1):e42. doi:10.1371/journal.pone.
0000042. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762400/ (accessed 24 Sep‐
tember 2012).
[173] Feldhahn M, Dönnes P, Schubert B, Schilbach K, Rammensee HG, Kohlbacher O. mi‐
HA-Match: Computational detection of tissue-specific minor histocompatibility anti‐
gens. J Immunol Methods. 2012; Sep 14. pii: S0022-1759(12)00275-X. doi: 10.1016/j.jim.
2012.09.004. http://www.sciencedirect.com/science/article/pii/S002217591200275X (ac‐
cessed 24 September 2012).
[174] Miller JS, Warren EH, Van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, et al.
NCI First International Workshop on The Biology, Prevention, and Treatment of Re‐
lapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the
Committee on the Biology Underlying Recurrence of Malignant Disease following
Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow
Transplant. 2010;16(5):565-86. http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2858433/ (accessed 13 August 2012).
[175] Spaapen R, Mutis T. Targeting haematopoietic-specific minor histocompatibility anti‐
gens to distinguish graft-versus-tumour effects from graft-versus-host disease. Best
Pract Res. 2008;21: 543-57. http://www.bprch.com/article/S1521-6926(08)00052-2/
abstract (accessed 14 September 2012).
[176] Kawase T, Akatsuka Y, Torikai H, Morishima S, Oka A, Tsujimura A et al. Alterna‐
tive splicing due to an intronic SNP in HMSD generates a novel minor histocompati‐
bility antigen. Blood 2007;110:1055-63. http://bloodjournal.hematologylibrary.org/
content/110/3/1055.long (accessed 14 August 2012).
[177] Mullally A, Ritz J, Beyond HLA. the significance of genomic variation for allogeneic
hematopoietic stem cell transplantation. Blood. 2007;109:1355-62. http://bloodjour‐
nal.hematologylibrary.org/content/109/4/1355.long (accessed 23 August 2012).
[178] Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen re‐
sulting from differential expression due to a gene deletion. J Exp Med
2003;197:1279-89. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193779/ (accessed
25 August 2012).
Innovations in Stem Cell Transplantation40
[179] Goulmy E, Termijtelen A, Bradley BA, et al. Y-antigen killing by T cells of women is
restricted by HLA. Nature 1977;266:544-5.http://www.ncbi.nlm.nih.gov/pubmed?
term=Y-antigen%20killing%20by%20T%20cells%20of%20women%20is%20restricted
%20by%20HLA (accessed 24 August 2012).
[180] Verdijk RM, Kloosterman A, Pool J, Van de Keur M, Naipal AMIH, Brand A et al.
Pregnancy induces minor Histocompatibility antigen specific cytotoxic T cells: impli‐
cations for stem cell transplantation and immunotherapy. Blood 2004;103:1961–4.
http://bloodjournal.hematologylibrary.org/content/103/5/1961.long (accessed 24 Au‐
gust 2012).
[181] Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Ap‐
perley J. Female donors influence transplant-related mortality and relapse incidence
in male recipients of sibling blood and marrow transplants. Hematol J. 2001;2(6):
363-70. http://www.ncbi.nlm.nih.gov/pubmed?term=Female%20donors%20influence
%20transplant-related%20mortality%20and%20relapse%20incidence%20in%20male
%20recipients%20of%20sib (accessed 01 August 2012).
[182] Kollman C, Howe CWS, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor
characteristics as risk factors in recipients after transplantation of bone marrow from
unrelated donors: the effect of donor age. Blood. 2001;98(7):2043-51. http://bloodjour‐
nal.hematologylibrary.org/content/98/7/2043.long (accessed 24 September 2012).
[183] Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors
contribute to a selective graft-versus-leukemia effect in male recipients of HLA-
matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347-52.
http://bloodjournal.hematologylibrary.org/content/103/1/347.long (accessed 24 Sep‐
tember 2012)
[184] Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM et al. Im‐
pact of donor and recipient sex and parity on outcomes of HLA-identical sibling allo‐
geneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant.
2006;12(7):758-69. http://www.bbmt.org/article/S1083-8791(06)00290-4/abstract (ac‐
cessed 23 August 2012).
[185] Stern M, Brand R, de Witte T, et al. Female-versus-male alloreactivity as a model for
minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J
Transplant. 2008;8(10):2149-57. http://onlinelibrary.wiley.com/doi/10.1111/j.
1600-6143.2008.02374.x/abstract (accessed 24 August 2012).
[186] Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to
H-Y minor histocompatibility antigens correlate with chronic graft-versus-host dis‐
ease and disease remission. Blood. 2005;105(7):2973-8. http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC1350982/ (Access 20 August 2012).
[187] Storb R, Prentice RL, Thomas ED. Treatment of aplastic anemia by marrow trans‐
plantation from HLA identical siblings. Prognostic factors associated with graft ver‐
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
41
sus host disease and survival. J Clin Invest. 1977;59(4):625-32. http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC372266/ (accessed 05 September 2012).
[188] Stern M, Passweg JR, Locasciulli A, Socié G, Schrezenmeier H, Bekássy AN et al. In‐
fluence of donor/recipient sex matching on outcome of allogeneic hematopoietic
stem cell transplantation for aplastic anemia. Transplantation. 2006;82(2):218-26.
http://www.ncbi.nlm.nih.gov/pubmed?term=Influence%20of%20donor%2Frecipient
%20sex%20matching%20on%20outcome%20of%20allogeneic%20hematopoietic
%20stem (accesse 02 September 2012).
[189] Hambach L, Spierings E, Goulmy E. Risk assessment in haematopoietic stem cell
transplantation: minor histocompatibility antigens. Best Pract Res. 2007;20:171-87.
http://www.bprch.com/article/S1521-6926(06)00062-4/abstract (accessed 02 Septem‐
ber 2012).
[190] Voogt PJ, Fibbe WE, Marijt WA, Veenhol, WFJ, Hamilton M, Zwaan FE. Rejection of
bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor his‐
tocompatibility antigens. Lancet 1990;335:131-4. http://www.ncbi.nlm.nih.gov/
pubmed?term=Rejection%20of%20bone-marrow%20graft%20by%20recipient-de‐
rived%20cytotoxic%20T%20lymphocytes%20against%20minor%20histocompatibility
%20antigens (accessed 02 September 2012).
[191] Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg F, Vossen J et al. Mismatches
of minor histocompatibility antigens between HLA-identical donors and recipients
and the deveopment of graft-versus-host disease after bone marrow transplantation.
N Engl J Med. 1996;334: 281-5. http://www.nejm.org/doi/full/10.1056/
NEJM199602013340501 (accessed 03 September 2012).
[192] Perez-Garcia A, De la Camara R, Torres A, Gonzalez M, Jimenez A, Gallardo. Minor
histocompatibility antigen HA-8 mismatch and clinical outcome after HLA-identical
sibling donor allogeneic stem cell transplantation. Haematologica. 2005;90:1723-4.
http://www.haematologica.org/content/90/12/1723.long (accessed 04 September
2012).
[193] Akatsuka Y, Warren EH, Gooley TA, Brickner AG, Lin MT, Hansen JA et al. Dispari‐
ty for a newly identified minor histocompatibility antigen, HA-8, correlates with
acute graft-versus-host disease after haematopoietic stem cell transplantation from
an HLA-identical sibling. Br J Haematol. 2003;123:671-5. http://
www.ncbi.nlm.nih.gov/pubmed?term=Disparity%20for%20a%20newly%20identified
%20minor%20histocompatibility%20antigen%2C%20HA-8%2C%20correlates
%20with%20acute%20graft-versus-host%20disease%20after%20haematopoietic
%20stem%20cell%20transplantation%20from%20an%20HLA-identical%20sibling.
(accessed 04 September 2012).
[194] McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD et al. Do‐
nor-recipient mismatch for common gene deletion polymorphisms in graft-versus-
host disease. Nat Genet. 2009;41(12):1341-4. http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC2804745/ (accessed 04 September 2012).
Innovations in Stem Cell Transplantation42
[195] de Rijke B, van Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, Woestenenk
R et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lympho‐
cyte response associated with remission of chronic myeloid leukemia. J Clin Invest.
2005;115:3506-16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297240/ (accessed
23 August 2012).
[196] Van Bergen CA, Kester MG, Jedema I, Heemskerk MHM, Van Luxemburg-Heijset
ASP, Kloosterboer FM et al. Multiple myeloma– reactive T cells recognize an activa‐
tion-induced minor histocompatibility antigen encoded by the ATP-dependent inter‐
feron-responsive (ADIR) gene. Blood 2007;109:4089-96. http://
bloodjournal.hematologylibrary.org/content/109/9/4089.long (accessed 23 August
2012).
[197] Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Frederik F, Griffioen
M et al. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens
as hematopoietic targets in antitumor immunity. Blood 2009;114:3684-92. http://
bloodjournal.hematologylibrary.org/content/114/17/3684.long (accessed 23 August
2012).
Immunogenetics of Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/54281
43

